Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/385—Haptens or antigens, bound to carriers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/0005—Vertebrate antigens
  • A61K39/0011—Cancer antigens
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/0005—Vertebrate antigens
  • A61K39/0011—Cancer antigens
  • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
  • A61K39/001168—Mesothelin [MSLN]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/0005—Vertebrate antigens
  • A61K39/0011—Cancer antigens
  • A61K39/00119—Melanoma antigens
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/002—Protozoa antigens
  • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/02—Bacterial antigens
  • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/12—Viral antigens
  • A61K39/145—Orthomyxoviridae, e.g. influenza virus
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K40/00—Cellular immunotherapy
  • A61K40/10—Cellular immunotherapy characterised by the cell type used
  • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K40/00—Cellular immunotherapy
  • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
  • A61K40/41—Vertebrate antigens
  • A61K40/42—Cancer antigens
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
  • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/51—Nanocapsules; Nanoparticles
  • A61K9/5107—Excipients; Inactive ingredients
  • A61K9/513—Organic macromolecular compounds; Dendrimers
  • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/51—Nanocapsules; Nanoparticles
  • A61K9/5107—Excipients; Inactive ingredients
  • A61K9/513—Organic macromolecular compounds; Dendrimers
  • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
  • A61K2039/55511—Organic adjuvants
  • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
  • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
  • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
  • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B82—NANOTECHNOLOGY
  • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
  • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• the present disclosure relates generally to the field of vaccine compositions. More particularly, it concerns vaccine compositions for use in an immunotherapy of cancer or an infectious disease.
• compositions which may be used to promote an immune response to a disease or disorder via the STING pathway.
• compositions comprising: (A) an antigen;
• the antigen is encapsulated by the copolymer.
• the antigen is an anti-cancer antigen.
• the antigen is a tumor-associated antigen or a tumor neoantigen.
• the tumor-associated antigen is a human papilloma virus E6 protein, E7 protein, or a fragment thereof such as LHEYMLDLQPETVDLDLLMGTLGIVCPICSQ (SEQ ID NO: 1) or DTPTLHEYMLDLQPETVDLYCYE (SEQ ID NO: 2).
• the tumor- associated antigen is mesothelin or a fragment thereof such as GQKMNAQAIALVACYLRGGGQLDEDMV (SEQ ID NO: 3).
• the anti-cancer antigen is a melanoma tumor associated antigen or a neoantigen such as
• VVDRNPQFLDPVLAYLMKGLCEKPLAS SEQ ID NO: 9
• the anti-cancer antigen is a bladder, blood, bone, brain, breast, central nervous system, cervix, colon, endometrium, esophagus, gall bladder, gastrointestinal tract, genitalia, genitourinary tract, head, kidney, larynx, liver, lung, muscle tissue, neck, oral or nasal mucosa, ovary, pancreas, prostate, skin, spleen, small intestine, large intestine, stomach, testicle, or thyroid cancer antigen.
• the anti-cancer antigen is a mesothelioma, melanoma, pancreatic, ovarian, or cervical cancer antigen.
• the antigen is a viral antigen.
• the viral antigen is a hepatitis B virus antigen such as a HBV surface (HBsAg), core (HBcAg) antigen, or a fragment thereof.
• the viral antigen is an influenza virus antigen such as a haemagglutinin antigen (HA), a neuroaminidase antigen (NA), or a fragment thereof.
• the viral antigen is a West Nile virus antigen such as an envelope protein (E), a premembrane protein (prM), or a fragment thereof.
• the viral antigen is a Dengue virus antigen such as a 80E subunit protein or a fragment thereof.
• the viral antigen is an Ebola virus antigen such as a glycoprotein (GP) or fragment thereof.
• the viral antigen is a HIV antigen such as a HIV envelope protein gp41, gpl20, or a fragment thereof.
• the antigen is a bacterial antigen such as a mycobacterium tuberculosis (Mtb) antigen such as recombinant Ag85A, Ag85B, ESAT6, TB10.4, or a fragment thereof.
• the antigen is a malaria antigen such as a circumsporozoite protein (CSP), sporozoite and liver-stage antigen (SALSA), merozoite surface protein (MSP) of Plasmodium falciparum, or a fragment thereof.
• CSP circumsporozoite protein
• SALSA sporozoite and liver-stage antigen
• MSP merozoite surface protein
• the diblock copolymer has a pKa in water from about 6 to about 7.5 as calculated by pH titration.
• the nanoparticle formed from the diblock copolymer is dissociates at a pH below the pKa.
• the diblock copolymer comprises a hydrophilic block and a hydrophobic block.
• the hydrophilic block is a PEG polymer, a PVP polymer, or a MPC polymer.
• the hydrophilic block is a PEG polymer.
• the hydrophobic block comprises an amine group which has a pKa from about 6 to about 7.5.
• the hydrophobic block becomes hydrophilic upon protonation of the amine group.
• the amine group is a cyclic amine group.
• the diblock copolymer is further defined by the formula:
• Ri is hydrogen, alkyl(c ⁇ i2), cycloalkyl(c ⁇ i2), substituted alkyl(c ⁇ i2), substituted cycloalkyl(c ⁇ i2);
• n is an integer from 1 to 500;
• R.2 and R2' are each independently selected from hydrogen, alkyl(c ⁇ i2), cycloalkyl(c ⁇ i2), substituted alkyl(c ⁇ i2), or substituted cycloalkyl(c ⁇ i2);
• R.3 is a group of the formula:
• n x is 1-10;
• Xi, X2, and X3 are each independently selected from hydrogen, alkyl(c ⁇ i2), cycloalkyl(c ⁇ i2), substituted alkyl(c ⁇ i2), or substituted cycloalkyl(c ⁇ i2); and
• X4 and X5 are each independently selected from alkyl(c ⁇ i2), cycloalkyl(c ⁇ i2), or a substituted version of any of these groups, or X4 and X5 are taken together and are alkanediyl(c ⁇ i2), alkoxydiyl(c ⁇ i2), alkylaminodiyl(c ⁇ i2), or a substituted version of any of these groups;
• x is an integer from 1 to 150;
• R.4 is a group of the formula:
• n y is 1-10;
• Xi', X 2 ', and X3' are each independently selected from hydrogen, alkyl(c ⁇ i2), cycloalkyl(c ⁇ i2), substituted alkyl(c ⁇ i2), or substituted cycloalkyl(c ⁇ i2); and
• X4' and X5' are each independently selected from hydrogen, alkyl(c ⁇ i2), cycloalkyl(c ⁇ i2), acyl(c ⁇ i2), substituted alkyl(c ⁇ i2), substituted cycloalkyl(c ⁇ i2), substituted acyl(c ⁇ i2), a dye, or a fluorescence quencher or X 4 ' and X5' are taken together and are alkanediyl(c ⁇ i2), alkoxydiyl(c ⁇ i2), alkylaminodiyl(c ⁇ i2), or a substituted version of any of these groups; y is an integer from 0 to 150;
• R.5 is hydrogen, halo, hydroxy, alkyl(c ⁇ i2), or substituted alkyl(c ⁇ i2),
• the diblock copolymer is further defined as:
• Ri is hydrogen, alkyl(c ⁇ i2), cycloalkyl(c ⁇ i2), substituted alkyl(c ⁇ i2), substituted cycloalkyl(c ⁇ i2);
• n is an integer from 1 to 500;
• R2 and R2' are each independently selected from hydrogen, alkyl(c ⁇ i2), cycloalkyl(c ⁇ i2), substituted alkyl(c ⁇ i2), or substituted cycloalkyl(c ⁇ i2);
• R3 is a group of the formula:
• X4 and X5 are each independently selected from alkyl(c ⁇ i2), cycloalkyl(c ⁇ i2), or a substituted version of either of these groups, or X4 and X5 are taken together and are alkanediyl(c ⁇ i2), alkoxydiyl(c ⁇ i2), alkylaminodiyl(c ⁇ i2), or a substituted version of any of these groups;
• x is an integer from 1 to 150;
• R4 is a group of the formula:
• X5' are each independently selected from hydrogen, alkyl(c ⁇ i2), cycloalkyl(c ⁇ i2), acyl(c ⁇ i2), substituted alkyl(c ⁇ i2), substituted cycloalkyl(c ⁇ i2), substituted acyl(c ⁇ i2), a dye, or a fluorescence quencher or X 4 ' and X5' are taken together and are alkanediyl(c ⁇ i2), alkoxydiyl(c ⁇ i2), alkylaminodiyl(c ⁇ i2), or a substituted version of any of these groups;
• y is an integer from 0 to 150;
• R.5 is hydrogen, halo, hydroxy, alkyl(c ⁇ i2), or substituted alkyl(c ⁇ i2),
• the diblock copolymer is further defined as:
• Ri is hydrogen, alkyl(c ⁇ i2), cycloalkyl(c ⁇ i2), substituted alkyl(c ⁇ i2), substituted cycloalkyl(c ⁇ i2);
• n is an integer from 1 to 500;
• R3 is a group of the formula:
• X 4 and X5 are each independently selected from alkyl(c ⁇ i2), cycloalkyl(c ⁇ i2), or a substituted version of either of these groups, or X 4 and X5 are taken together and are alkanediyl(c ⁇ i2), alkoxydiyl(c ⁇ i2), alkylaminodiyl(c ⁇ i2), or a substituted version of any of these groups;
• x is an integer from 1 to 150;
• R.4 is a group of the formula:
• X 4 ' and X5' are each independently selected from hydrogen, alkyl(c ⁇ i2), cycloalkyl(c ⁇ i2), acyl(c ⁇ i2), substituted alkyl(c ⁇ i2), substituted cycloalkyl(c ⁇ i2), substituted acyl(c ⁇ i2), a dye, or a fluorescence quencher or X 4 ' and X5' are taken together and are alkanediyl(c ⁇ i2), alkoxydiyl(c ⁇ i2), alkylaminodiyl(c ⁇ i2), or a substituted version of any of these groups;
• y is an integer from 0 to 15;
• R.5 is hydrogen, halo, hydroxy, alkyl(c ⁇ i2), or substituted alkyl(c ⁇ i2),
• the diblock copolymer further defined as:
• Ri is hydrogen, alkyl(c ⁇ i2), cycloalkyl(c ⁇ i2), substituted alkyl(c ⁇ i2), substituted cycloalkyl(c ⁇ i2);
• n is an integer from 1 to 500;
• R3 is a group of the formula:
• X4 and X5 are each independently selected from alkyl(c ⁇ i2), cycloalkyl(c ⁇ i2), or a substituted version of either of these groups, or X4 and X5 are taken together and are alkanediyl(c ⁇ i2), alkoxydiyl(c ⁇ i2), alkylaminodiyl(c ⁇ i2), or a substituted version of any of these groups;
• x is an integer from 1 to 150;
• R.5 is hydrogen, halo, hydroxy, alkyl(c ⁇ i2), or substituted alkyl(c ⁇ i2),
• Ri is alkyl(c ⁇ i2) such as methyl.
• n is 50 to 200. In some embodiments, n is 75 to 150. In some embodiments, n is 114.
• X4 is alkyl(c ⁇ i2) or cycloalkyl(c ⁇ i2). In some embodiments, X4 is alkyl(c ⁇ i2) such as ethyl, isopropyl, ⁇ -propyl, w-butyl, or w-pentyl. In some embodiments, X4 is alkyl(ci-3). In some embodiments, X5 is alkyl(c ⁇ i2) or cycloalkyl(c ⁇ i2). In some embodiments, X5 is alkyl(c ⁇ i2) such as ethyl, isopropyl, ⁇ -propyl, n- butyl, or w-pentyl.
• X4 is alkyl(ci-3). In some embodiments, X4 and X5 are taken together and are alkanediyl(c ⁇ i2), alkoxydiyl(c ⁇ i2), alkylaminodiyl(c ⁇ i2), or a substituted version of any of these groups. In some embodiments, X4 and X5 are taken together and are alkanediyl(c ⁇ i2) or substituted alkanediyl(c ⁇ i2).
• X4 and X 5 are taken together and are -CH2CH2CH2CH2CH2-, -CH2CH2CH2CH2CH2-, -CH2CH2CH2CH2CH2CH2-, -CH2CH2CH(CH 3 )CH 2 CH2-, or
• x is 50 to 120. In some embodiments, x is 60 to 100. In some embodiments, y is 0. In other embodiments, y is 1, 2, 3, 4, or 5.
• X4' is a dye such as a fluorescent dye or a fluorescence quencher. In some embodiments, X 4 ' is alkyl(c ⁇ i2). In some embodiments, X 4 ' and X5' are taken together and are alkanediyl(c ⁇ i2). In some embodiments, X5' is hydrogen. In some embodiments, X5' is alkyl(c ⁇ i2).
• the di block copolymer is PEG114-&-PDEA70, PEG114-&- PEPA70, PEGii4-*-PDPA 7 o, PEGii4-Z>-PDBA 70 , PEGii4-Z>-PD5A 70 , PEGii4-Z>-PC6A 70 , PEGii4-*-PC7A 7 o, PEGii4-Z>-PC8A 70 , PEGii4-*-PC6SlA 7 o, or PEGii4-*-PC6S2A 7 o.
• the diblock copolymer is PEGii4-Z>-PEPA 7 o, PEGii4-Z>-PC6A 7 o, PEG114- )- PC7A 70 , PEGii4-Z>-PC6S lA 70 , or PEGii4-*-PC6S2A 7 o.
• the compositions further comprise a solvent.
• the solvent is water.
• the solvent is an aqueous buffer such as phosphate buffered saline (PBS).
• PBS phosphate buffered saline
• the compositions activate the STING pathway.
• the compositions activate the interferon receptor pathway.
• compositions comprising an adjuvant and an antigen which activates the STING pathway and the adjuvant forms a nanoparticle.
• compositions comprising an adjuvant and an antigen which activates one or more interferon receptor proteins and the adjuvant forms a nanoparticle.
• compositions comprising:
• the composition is a nanoparticle comprising a particle size of less than 50 nm, a plurality of heterocycloalkyl groups on the adjuvant, wherein at least one of the heteroatoms in the heterocycloalkyl group is a nitrogen atom, and a pH transition point from about 6.5 to 7.4.
• the particle size is from 5 nm to 50 nm.
• the plurality of heterocycloalkyl group is from 10 to 200 heterocylcoalkyl groups.
• the plurality of heterocycloalkyl group is from 40 to 160 heterocylcoalkyl groups.
• the heterocycloalkyl group is azepane.
• the pH transition point is from 6.5 to 7.2. In some embodiments, the pH transition point is from 6.8 to 7.0.
• compositions comprising:
• the pharmaceutical compositions are formulated for injection. In some embodiments, the pharmaceutical compositions are formulated for intravenous, intramuscular, intraperitoneal, or subcutaneous injection. In some embodiments, the pharmaceutical compositions are formulated as a unit dose. [0016] In some embodiments, the pharmaceutical compositions further comprise a second active agent. In some embodiments, the second active agent is a checkpoint inhibitor. In some embodiments, the checkpoint inhibitor is a PD-1 inhibitor. In some embodiments, the PD-1 inhibitor is an anti-PD-1 antibody. the anti-PD-I antibody is nivolumab, pembrolizumab, BMS 936559, MPDL3280A, or pidihzumab.
• the present disclosure provides methods of treating a disease or disorder in a patient in need thereof comprising administering to the patient a therapeutically effective amount of the compositions described herein.
• the disease or disorder is cancer.
• the cancer is a carcinoma, sarcoma, lymphoma, leukemia, melanoma, mesothelioma, multiple myeloma, or seminoma.
• the cancer is of the bladder, blood, bone, brain, breast, central nervous system, cervix, colon, endometrium, esophagus, gall bladder, gastrointestinal tract, genitalia, genitourinary tract, head, kidney, larynx, liver, lung, muscle tissue, neck, oral or nasal mucosa, ovary, pancreas, prostate, skin, spleen, small intestine, large intestine, stomach, testicle, or thyroid.
• the cancer is melanoma mesothelioma, or cervical cancer.
• the methods further comprise a second anti-cancer therapy.
• the second anti-cancer therapy is surgery, chemotherapeutic, radiation therapy, gene therapy, or second immunotherapy.
• the second anti-cancer therapy is a second immunotherapy.
• the second immunotherapy is a checkpoint therapy.
• the immunotherapy is an inhibitor of PD-1.
• the immunotherapy is nivolumab, pembrolizumab, pidihzumab, BMS 936559, or MPDL3280A.
• the second anti-cancer therapy is radiation therapy.
• the radiation therapy is administered two or more times
• the composition is administered two or more times, or both are administered two or more times.
• the disease or disorder is an infectious disease. In some embodiments, the disease or disorder is malaria. In some embodiments, the disease or disorder is a viral infection such as HIV, Hepatitis B, Ebola, dengue, or West Nile virus. In other embodiments, the disease or disorder is a bacterial infection such as tuberculosis. In other embodiments, the disease or disorder is an autoimmune disease. [0021] In some embodiments, the patient is a mammal. In some embodiments, the patient is a human. In some embodiments, the methods comprise administering the composition once. In other embodiments, the methods comprise administering the composition two or more times.
• the present disclosure provides methods of activating the STING pathway in a patient comprising administering to the patient in need thereof a composition comprising an antigen and an adjuvant wherein the adjuvant forms a nanoparticle.
• the adjuvant is a synthetic polymer.
• FIGS. 1A-D PC7A NP induces robust antigen-specific CTL and Thl responses.
• FIG. 1A Schematic of CFSE method to screen for polymer structures that generate strong OVA-specific CTL response. OVA was used as a model antigen (10 ⁇ g) and loaded in different polymer NPs (30 ⁇ g).
• FIGS. 2A-G PC7A NP improves antigen delivery and cross-presentation in APCs and stimulates CD8 T cell responses.
• FIG. 2B Schematic of detection of antigen cross-presentation in BMDCs and CD8 + T cell activation in vitro.
• FIGS. 2E, 2C-E and 2G representative data from three independent experiments are presented as means ⁇ s.e.m.. Statistical significance was calculated by Student's /-test, ***P ⁇ 0.001, **P ⁇ 0.01, *P ⁇ 0.05. NS, not significant.
• FIGS. 3A-F PC7A NP activates APCs in draining lymph nodes and stimulates STING-dependent adaptive immune responses.
• FIGS. 4A-G PC7A nanovaccine inhibits tumor growth and prolongs survival in tumor bearing mice.
• FIG. 4A Schematic of the minimalist design of PC7A nanovaccine.
• Tumor growth FIG. 4B
• Kaplan-Meier survival curves FIG. 4C
• FIG. 4D Tumor growth inhibition study of B16F10 melanoma.
• mice inoculated with 1.0* 10 6 MC38 tumor cells were treated with a cocktail of neoantigens (Repslp45A, AdpgkR304M, Dpagtlv2i3L) in PC7A NP, and nanovaccine was administered on day 10 and 15 in established tumors (100-200 mm 3 ).
• FIGS. 4B and 4D-F data are presented as means ⁇ s.e.m..
• FIGS. 5A-C Syntheses and pH titration of ultra-pH sensitive (UPS) PEG- Z>-PR block copolymers.
• FIG. 5B Characterization of the copolymers from the library. Number-averaged molecular weight (Mn) was determined by GPC using THF as the eluent; pKa was determined by pH titration of polymer solutions using 4 M NaOH.
• FIGS. 6A-D Efficient loading of OVA in PC7A NP through a physical mixing procedure.
• FIG. 6A The OVA loading efficiency in the micelle nanoparticles was measured by an ultrafiltration method.
• FIG. 6B Loading stability of OVA in PC7A micelles was examined in PBS buffer (pH 7.4) containing 5% fetal bovine serum at different time points.
• FIG. 6C Schematic synthesis of dye-conjugated PEG-&-PC7A copolymer. Cy3.5 was used as a dye example.
• FIGS. 6D Fluorescence spectra of Cy3.5 labelled PC7A, AF647- OVA and PC7A+OVA mixture, which showed strong fluorescence resonance electron transfer (FRET) effect in the mixture group indicating OVA loading inside PC7A NP.
• FRET fluorescence resonance electron transfer
• PC7A NP improves antigen delivery in draining lymph nodes, induces LN inflammation and APC maturation.
• FIG. 7B Midline cross-section (maximal surface) of resected draining lymph nodes from C57BL/6 mice showed enlarged nodes by PC7A NP over OVA alone.
• FIG. 7C Quantification of total cell numbers in the draining lymph nodes at 24 h.
• FIGS. 7C-D representative data from three independent experiments are presented as means ⁇ s.e.m. Statistical significance was calculated by Student's /-test, ***P ⁇ 0.001, **P ⁇ 0.01, *P ⁇ 0.05. NS, not significant.
• FIGS. 8A-B PC7A NP disrupts membranes at acidic pH.
• FIGS. 8A-B PC7A NP disrupts membranes at acidic pH.
• FIG. 8A Hemolytic analysis of the red blood cells after treatment with PC7A or PD5A copolymers in different pH medium.
• representative data from three independent experiments are presented as means ⁇ s.e.m.
• FIG. 9A-J PC7A NP activates type I IFN-induced genes through STING pathway.
• cGAMP a STING activator transfected by lipofectamine was used as a positive control. Results show STING- dependent expression of CXCL10 in both cell lines.
• FIG. 9C BMDMs were transfected with DNase I for 1 hr, and followed by treatment with PC7A NP.
• FIG. 9D PC7A NP treated THP-1 cells resulted in pulldown of STING proteins by streptavidin modified dynabeads. PD5A-biotin and PC7A only (biotin free) controls did not show any STING pulldown.
• FIG. 9E Direct pulldown assay of purified human STING C-terminal domain (CTD, 139-379AAs). PC7A-biotin copolymer pulled down STING CTD, but not other copolymers or PC7A only control.
• FIG. 9F Titration of PC7A binding to STING CTD by isothermal calorimetry (ITC) experiments.
• FIG. 9G Summary of binding affinity in ITC experiment. Negligible binding was found between PC7A and BSA.
• FIG. 91 Human THP-1 and (FIG.
• FIGS. 9A-C, and FIGS. 9I-J representative data from three independent experiments are presented as means ⁇ s.e.m..
• FIG. 9H representative data from two independent experiments are presented as means ⁇ s.e.m.
• Statistical significance was calculated by Student's /-test, ***P ⁇ 0.001, **P ⁇ 0.01, *P ⁇ 0.05. NS, not significant.
• FIGS. 10A-D APCs are the major cell population that take up PC7A NP and activate STING pathway in vivo.
• FIG. 10A Comparative assessment of CD45+NP+ and CD45+NP- cells in LNs.
• FIG. 10B Phenotypic analysis of NP+ and NP- cells in LNs by flow cytometry.
• FIG. IOC Assessment of NP accumulated cells (NP+) in both CD45+ and CD45- cells from subcutaneous tissue.
• FIG. 10D Phenotypic analysis of CD45+NP- and CD45+ NP+ cells in subcutaneous tissue by flow cytometry.
• FIGS. 10A and IOC representative data from two independent experiments are presented as means ⁇ s.e.m. Statistical significance was calculated by Student's /-test, ***P ⁇ 0.001. NS, not significant.
• FIGS. 11A-F PC7A nanovaccine inhibits tumor growth and prolongs survival.
• OVA peptide 0.5 ⁇ g
• OVAp-PD5A NP OVAp-PD5A NP
• PC7A alone or OVAp-PC7A NP had no observable effect in tumor growth inhibition (FIG. 11A) or animal survival curves (FIG. 11B).
• FIG. 11C Tumor growth inhibition of B16F10 treated by neoantigen-PC7A NP.
• FIGS. 11A and 11C-F data are presented as means ⁇ s.e.m.
• FIGS. 12A-F Synergy effect of nanovaccine and anti-PD-1 antibody in two tumor models.
• FIG. 12A C57BL/6 mice inoculated with 1.5 ⁇ 10 5 B16-OVA tumor cells were treated with OVA peptide, PC7A nanovaccine, anti-PD-1 alone and anti-PD-1 in combination with PC7A nanovaccine. Kaplan-Meier survival curves of tumor-bearing mice were shown.
• FIG. 12A C57BL/6 mice inoculated with 1.5 ⁇ 10 5 B16-OVA tumor cells were treated with OVA peptide, PC7A nanovaccine, anti-PD-1 alone and anti-PD-1 in combination with PC7A nanovaccine. Kaplan-Meier survival curves of tumor-bearing mice were shown.
• FIG. 12A C57BL/6 mice inoculated with 1.5 ⁇ 10 5 B16-OVA tumor cells were treated with OVA peptide, PC7A nanovaccine, anti-PD-1 alone and anti-PD-1 in combination with PC7A nano
• FIG. 12C Individual tumor growth curves for OVAp alone, OVAp-PC7A NP, and OVAp-PC7A NP combined with anti-PD-1.
• FIG. 12B The PD-L1 expression profile in B16-OVA tumors.
• the PD-L1 were highly expressed in MDSCs (CDl lb+Grl+) and macrophages (CDl lb+F4/80+) over the isotype control whereas the expression in DCs (CDl lc+) and B16- OVA melanoma cells (CD45-) are modest.
• FIG. 12E Individual tumor growth curves for E7p alone, E7p-PC7A NP, and E7p-PC7A NP combined with anti-PD-1. Data show 50% and 90% of mice had tumor-free survival in the E7p-PC7A NP and E7p-PC7A NP/anti-PD-1 groups, respectively.
• FIG. 13 PC7A nanovaccine showed less systemic cytokine levels compared to Poly(I:C) control.
• Systemic cytokines and chemokines in the serum were measured over time by bead-based Bio-Plex Pro Mouse Cytokine 23-plex Assay.
• IL-la, IL-2, IL-3, IL-4, IL-5, IL-9, IL-10, IL-12 (p70), IL- 13, IL-17, GM-CSF did not show any significant difference in all groups and were not included in this figure.
• Data are presented as means ⁇ s.e.m. Statistical significance was calculated by Student's ⁇ -test, ***P ⁇ 0.001, **P ⁇ 0.01, *P ⁇ 0.05.
• FIG. 15 Comparison of OVA-specific CTL responses in different NP groups by in vivo cytotoxicity killing assay.
• FIGS. 16A-16C Evaluation of physical loading versus covalent conjugation of peptide antigens on CTL response.
• FIG. 16A Two synthetic routes of peptide conjugation to the surface or core of the PEG-&-PC7A micelle nanoparticles for antigen loading.
• FIG. 16B Schematic illustration of the nanovaccines as produced from three different strategies.
• FIGS. 17A-E Mice vaccinated with the influenza virus H1N1 HA antigen and PC7A nanoparticle produced anti-HA antibodies and are protected from lethal infections by the H1N1 influenza virus.
• FIGS. 17A-C circulating anti-HlNl HA total IgG (FIG. 17 A) levels were measured by ELISA in serum harvested from vaccinated mice one week post-boost. Circulating anti-HlNl HA IgGl (FIG. 17B) and IgG2b (FIG. 17C) levels in vaccinated mouse sera were also measured.
• B6 WT mice (n 5/group) were primed i.m.
• mice were vaccinated intranasally challenged with lOx MLD50 (median lethal dose for 50% mortality) of influenza A/PR/8/34 (H1N1) virus 1.5 weeks post-boost. Bodyweight (FIG. 17D) and survival (FIG. 17E) were tracked daily for two weeks.
• FIG. 18 Nanovaccine combined with radiation therapy (RT) can induce regression of established HPV tumors.
• the nanovaccine (30 ⁇ g PC7A+0.5 ⁇ g peptide E743-62 (GQAEPDRAHYNIVTFCCKCD, SEQ ID NO: 26) was injected subcutaneously onto the back of mice at the tail base. Six days later, the mice were boosted with another injection of nanovaccine with the same dose.
• Tumor growth was subsequently measured twice a week using a digital caliper and calculated as 0.5 xlength ⁇ width 2 by blinded investigators. Mice were sacrificed when tumor size reached 1500 mm 3 .
• the combined nanovaccine and radiation therapy showed significantly improved therapeutic synergy over radiation or nanovaccine alone treatment.
• the present disclosure provides vaccine compositions which may be used to generate an immune response to a disease antigen such as cancer or an infectious disease. These vaccine compositions may activate the STING and/or the interferon receptor pathways in vivo leading to an enhanced immunoresponse.
• the vaccine compositions comprise an antigen and a pH sensitive diblock copolymer. These compositions may be used in the treatment of various diseases and disorders such as cancer or an infectious disease.
• compositions described herein may comprise one or more immunostimulatory agents.
• Immunostimulatory agents include but are not limited to an antigen or antigenic compound, an immunomodulator, an APC, an adjuvant or a carrier.
• Other immunopotentiating compounds are also contemplated for use with the compositions of the present disclosure such as polysaccharides, including chitosan, which is described in U.S. Patent 5,980,912, which is incorporated herein by reference.
• Multiple (more than one) antigens may be crosslinked to one another (e.g., polymerized).
• the use of small peptides for antibody generation or vaccination also may require conjugation of the peptide to an immunogenic carrier protein.
• Immuno response includes both cellular and humoral immune responses.
• B lymphocyte assays are well known, such as ELISAs, proliferation assays using peripheral blood lymphocytes (PBL), cytokine production and antibody production assays. See Benjamini et al. (1991), which is incorporated herein by reference.
• compositions one or more antigenic components An antigen is a substance which promotes an immune response such that antibodies are generated against the substance specifically. Some substances are more immunogenic and thus the immune system will readily develop an appropriate immune response but other substances require assistance to generate an immune response sufficient to generate antibodies against the antigen. Most cancers may require additional activation to enhance the generation of antibodies against the antigen.
• Some non-limiting examples of antigens include proteins or fragments thereof of cancer specific surface proteins or surface proteins overexpressed by cancer cells. Additionally, the antigen may be one of the peptides or proteins included in Table 1 : Table 1: Sequence of Some Non-Limiting Examples of Protein and Peptide Antigens
• antigens for specific indications including several different infectious diseases, toxins, and cancers are contemplated herein.
• Bacterial Pathogens for specific indications including several different infectious diseases, toxins, and cancers are contemplated herein.
• tuberculosis caused by the bacterium Mycobacterium tuberculosis, which kills about 2 million people a year, mostly in sub-Saharan Africa.
• mycobacterium tuberculosis antigens include recombinant Ag85A, Ag85B, ESAT6, TBI 0.4, or fragments thereof including those taught by Ottenhoff and Kaufmann, 2012, which is incorporated herein by reference.
• Pathogenic bacteria contribute to other globally important diseases, such as pneumonia, which can be caused by bacteria such as Streptococcus and Pseudomonas, and foodborne illnesses, which can be caused by bacteria such as Shigella, Campylobacter, and Salmonella.
• Pathogenic bacteria also cause infections such as tetanus, typhoid fever, diphtheria, syphilis, and leprosy.
• Conditionally pathogenic bacteria are only pathogenic under certain conditions, such as a wound facilitates entry of bacteria into the blood, or a decrease in immune function.
• Staphylococcus or Streptococcus are also part of the normal human flora and usually exist on the skin or in the nose without causing disease, but can potentially cause skin infections, pneumonia, meningitis, and even overwhelming sepsis, a systemic inflammatory response producing shock, massive vasodilation and death.
• Some species of bacteria such as Pseudomonas aeruginosa, Burkholderia cenocepacia, and Mycobacterium avium, are opportunistic pathogens and cause disease mainly in people suffering from immunosuppression or cystic fibrosis.
• Other bacterial invariably cause disease in humans such as obligate intracellular parasites (e.g., Chlamydophila, Ehrlichia, Rickettsia) that are capable of growing and reproducing only within the cells of other organisms. Still, infections with intracellular bacteria may be asymptomatic, such as during the incubation period.
• An example of intracellular bacteria is Rickettsia.
• Rickettsia One species of Rickettsia causes typhus, while another causes Rocky Mountain spotted fever.
• Chlamydia another phylum of obligate intracellular parasites, contains species that can cause pneumonia or urinary tract infection and may be involved in coronary heart disease.
• Vaccines may be developed for any viral pathogen for which protective antibodies are available. These include respiratory viruses such as Adenoviruses, Avian influenza. Influenza virus type A, Influenza virus type B, Measles, Parainfluenza virus, Respiratory syncytial virus (RSV), Rhinoviruses, and SARS-CoV, gastro-enteric viruses such as Coxsackie viruses, enteroviruses such as Poliovirus and Rotavirus, hepatitis viruses such as Hepatitis B virus, Hepatitis C virus, Bovine viral diarrhea virus (surrogate), herpesviruses such as Herpes simplex 1, Herpes simplex 2, Human cytomegalovirus, and Varicella zoster virus, retroviruses such as Human immunodeficiency virus 1 (HIV-1), and Human immunodeficiency virus 2 (HIV-2), as well as Dengue virus, Hantavirus, Hemorrhagic fever viruses, Lymphocytic choromeningit
• Some non-limiting viral antigens include hepatitis B virus HBV surface and core antigens, influenza virus haemagglutinin and neuroaminidase antigens, West Nile virus envelop protein (E) and premembrane protein (prM), Dengue virus 80E subunit protein, Ebola virus glycoprotein, HIV envelope protein gp41 and gpl20, or fragments thereof.
• Other HIV antigens can be found in de Taeye, et al, 2016, which is incorporated herein by reference. An antigen for any of these viral pathogens may be used in the present compositions. iii. Fungal Pathogens
• Pathogenic fungi are fungi that cause disease in humans or other organisms.
• Candida species are important human pathogens that are best known for causing opportunist infections in immunocompromised hosts (e.g. , transplant patients, AIDS sufferers, and cancer patients). Infections are difficult to treat and can be very serious. Aspergillus can and does cause disease in three major ways: through the production of mycotoxins; through induction of allergenic responses; and through localized or systemic infections. With the latter two categories, the immune status of the host is pivotal. The most common pathogenic species are Aspergillus fiimigatus and Aspergillus flavus. Cryptococcus neoformans can cause a severe form of meningitis and meningo-encephalitis in patients with HIV infection and AIDS.
• Cryptococcus laurentii and Cryptococcus albidus have been known to occasionally cause moderate-to-severe disease in human patients with compromised immunity.
• Cryptococcus gattii is endemic to tropical parts of the continent of Africa and Australia and can cause disease in non-immunocompromised people.
• Histoplasma capsulatum can cause histoplasmosis in humans, dogs and cats.
• Pneumocystis jirovecii or Pneumocystis carinii
• Stachybotrys chartarum or "black mold” can cause respiratory damage and severe headaches. It frequently occurs in houses in regions that are chronically damp. Antigens from these fungi may be included in the compositions described herein. iv. Parasites
• Parasite presents a major health issue, particularly in under-developed countries around the world.
• Significant pathogenic parasites include Entamoeba histolytica, Giardia lamblia, Trichomonas vaginalis, Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale, Plasmodium vivax, Trypanosoma gambiense, Trypanosoma rhodesiense, Trypanosoma cruzi, Ascaris lumbricoides, Trichinella spiralis, Toxoplasma gondii, Leishmania donovani, Leishmania tropica, Leishmania braziliensis, Schistosoma mansoni, Schistosoma japonicum, Schistosoma haematobium, and Pneumocystis jiroveci.
• Antigens from malaria parasites may include but are not limited to circumsporozoite protein (CSP), sporozoite and liver-stage antigen (SALSA), merozoite surface protein (MSP) of Plasmodium falciparum, or fragments thereof as well as those described in Carvalho, et al. , 2002, which is incorporated herein by reference. Antigens from these parasites may be included in the compositions described herein. v. Toxins
• Biotoxins are biological in nature, i.e., they are produced by many living organisms, including bacteria, insects, snakes and plants. These include a wide variety of insect toxins, such as spider, scorpion, bee wasp, or ants, snake toxins, many of which are neurotoxins to hemotoxins, cyanotoxins, jellyfish toxins, ricin, botulism toxin, tetanus toxoid and mycotoxins.
• Environmental toxins are toxins that are non-biological in origin, and can be natural or man-made. These include industrial and agricultural chemicals such as phthalates, polychlorinated biphenyls (PCBs), pesticides, dioxin, asbestos, chlorine, chloroform, volatile organic compounds (VOCs), and heavy metals such as lead, cadmium and arsenic. Any of these toxins may be used in the present compositions to promote an immune response. vi. Cancer
• a variety of different peptides, protein fragments, or proteins may be used as antigens in the present compositions.
• Some non-limiting examples include 5T4, 707-AP (707 alanine proline), 9D7, AFP (a-fetoprotein), AlbZIP HPG1, a5 i-Integrin, a5 6-Integrin, a- methylacyl-coenzyme A racemase, ART-4 (adenocarcinoma antigen recognized by T cells 4), B7H4, BAGE-1 (B antigen), BCL-2, BING-4, CA 15-3/CA 27-29, CA 19-9, CA 72-4, CA125, calreticulin, CAMEL (CTL-recognized antigen on melanoma), CASP-8 (caspase-8), cathepsin B, cathepsin L, CD 19, CD20, CD22, CD25, CD30, CD33, CD40, CD52, CD55, CD56, CD80, CEA (
• mutant antigens expressed in cancer diseases selected from the group comprising, without being limited thereto, a-actinin-4/m, ARTCl/m, bcr/abl (breakpoint cluster region-Abelson fusion protein), ⁇ -Catenin/m ( ⁇ -Catenin), BRCAl/m, BRCA2/m, CASP-5/m, CASP-8/m, CDC27/m (cell-division-cycle 27), CDK4/m (cyclin-dependent kinase 4), CDK 2A/m, CML66, COA-l/m, DEK-CAN (fusion protein), EFTUD2/m, ELF2/m (Elongation factor 2), ETV6-AML1 (Ets variant gene6/acute myeloid leukemia 1 gene fusion protein), FNl/m (fibronectin 1), GPNMB/m, HLA-A*0201-R170I (arginine to isoleucine exchange at residue 170 of the a-helix of the a
• antigens to prions proteinaceous infectious particles
• diseases such as mad cow and kuru
• antigens from small insects that embed themselves in the skin such as ticks, bed bugs or lice can be subject to a host immune response from the present compositions.
• diblock copolymers described herein may act as adjuvants in immunogenic compositions.
• the pH-responsive micelles and nanoparticles disclosed herein comprise block copolymers.
• a block copolymer comprises a hydrophilic polymer segment and a hydrophobic polymer segment.
• the hydrophobic polymer segment is pH sensitive.
• the hydrophobic polymer segment may comprise an ionizable amine group to render pH sensitivity.
• multiple different monomers e.g. 1, 2, 3, or more different monomers
• the block copolymers form pH-activatable micellar (pHAM) nanoparticles based on the supramolecular self-assembly of these ionizable block copolymers.
• pHAM pH-activatable micellar
• the ionizable groups may act as tunable hydrophilic/hydrophobic blocks at different pH values, which may directly affect the dynamic self-assembly of micelles.
• the block copolymers have a pH transition value, which is the pH value that the block copolymer go from a nanoparticle to a dissociated form.
• the pH transition value may from 6.0 to 7.4, from 6.5 to 7.4, from 6.5 to 7.2, from 6.8 to 7.4, from 6.8 to 7.2, or from 6.0, 6.2, 6.4, 6.5, 6.6, 6.7, 6.8, 6.85, 6.9, 6.95, 7.0, 7.05, 7.1, 7.2 to 7.4, or any range derivable therein.
• the block copolymers form a nanoparticle with a particle size of less than 50 nm.
• the nanoparticle may have a particle size from 1 nm to 50 nm, from 5 nm to 50 nm, from 10 nm to 50 nm, from 10 nm to 40 nm, from 20 nm to 40 nm, or from 5 nm, 10 nm, 15 nm, 20 nm, 22 nm, 24 nm, 26 nm, 28 nm, 30 nm, 32 nm, 34 nm, 35 nm, 40 nm, 45 nm to 50 nm, or any range derivable therein.
• the hydrophilic polymer segment comprises poly( ethylene oxide) (PEO). In some embodiments, the hydrophilic polymer segment comprises poly(methacrylate phosphatidyl choline) (MPC). In some embodiments, the hydrophilic polymer segment comprises polyvinylpyrrolidone (PVP). In general, the PEO, MPC, or PVP polymer in the hydrophilic polymer segment is about 2 kD to about 20 kD in size. In some embodiments, the polymer is about 2 kD to about 10 kD in size. In some embodiments, the polymer is about 2 kD to about 5 kD in size.
• the polymer is about 3 kD to about 8 kD in size. In some embodiments, the polymer is about 4 kD to about 6 kD in size. In some embodiments, the polymer is about 5 kD in size. In some embodiments, the polymer has about 100 to about 130 monomer units. In some embodiments, the polymer has about 110 to about 120 monomer units. In some embodiments, the polymer has about 114 monomer units.
• Suitable hydrophilic polymer segments for use as the hydrophilic block of the diblock copolymer may be prepared using methods known in the art or may be purchased. For example, MPC polymers (e.g.
• MPC polymers can be prepared by atom transfer radical polymerization (ATRP) with commercially available small molecule initiators such as ethyl 2-bromo-2-methylpropanoate (Sigma Aldrich). These resulting MPC polymers can be used as macromolecular A TRP initiators to further copolymerize with other monomers to form block polymers such as MPC-b-PDPA.
• PEO-&-PR block copolymers can be synthesized using atom transfer radical polymerization (ATRP) or reversible addition fragmentation chain transfer (RAFT) methods (See e.g.
• the hydrophobic polymer segment is prepared using amine containing methacrylate units which are pH sensitive.
• the hydrophobic polymer segment may comprise a polymer with x repeating units.
• x is about 40 to about 100 in total.
• x is about 50 to about 100 in total.
• x is about 40 to about 70 in total.
• x is about 60 to about 80 in total.
• the hydrophobic polymer segment may be synthesized according to, e.g. atom transfer radical Polymerization (ATRP) or reversible addition-fragmentation chain transfer (RAFT) or as described in the Examples below.
• ATRP atom transfer radical Polymerization
• RAFT reversible addition-fragmentation chain transfer
• the hydrophobic polymer segment contains a repeating unit wherein X4 and X5 are an alkyl group with C1-C3 carbon atoms or are taken together and have C4-C8 carbon atoms. In some embodiments, these carbon atom lengths are optimized to obtain a hydrophobic polymer segment with a pKa from about 6.0 to about 7.5. In some embodiments, the pKa is from about 6.5 to about 7.4. pK a may be measured using methods known to a person of skill in the art such as a pH titration.
• the immunogenicity of a particular immunogen composition can be enhanced by the use of non-specific stimulators of the immune response, known as adjuvants.
• adjuvants have been used experimentally to promote a generalized increase in immunity against poorly immunogenic antigens (e.g. , U.S. Patent 4,877,611). Immunization protocols have used adjuvants to stimulate responses for many years, and as such adjuvants are well known to one of ordinary skill in the art. Some adjuvants affect the way in which antigens are presented. For example, the immune response is increased when protein antigens are adsorbed to alum. Emulsification of antigens also prolongs the duration of antigen presentation and initiates an innate immune response.
• Suitable molecule adjuvants include all acceptable immunostimulatory compounds, such as cytokines, toxins or synthetic compositions. [0069] In some aspects, the compositions described herein may further comprise another adjuvant.
• Alum is an approved adjuvant for humans, adjuvants in experimental animals include complete Freund's adjuvant (a non-specific stimulator of the immune response containing killed Mycobacterium tuberculosis), incomplete Freund's adjuvants and aluminum hydroxide adjuvant.
• IL Interleukin
• IL-2 Interleukin-2
• IL-4 IL-7
• IL-12 interferon
• Bacillus Calmette-Guerin (BCG) Bacillus Calmette-Guerin
• aluminum hydroxide aluminum hydroxide
• muramyl dipeptide (MDP) compounds such as thur-MDP and nor-MDP (N-acetylmuramyl-L-alanyl-D-isoglutamine MDP), lipid A, and monophosphoryl lipid A (MPL).
• RIBI which contains three components extracted from bacteria, MPL, trehalose dimycolate (TDM) and cell wall skeleton (CWS) in a 2% squalene/Tween 80 emulsion also is contemplated. MHC antigens may even be used.
• an adjuvant effect is achieved by use of an agent, such as alum, used in about 0.05 to about 0.1% solution in phosphate buffered saline.
• an agent such as alum
• the antigen is made as an admixture with synthetic polymers of sugars (Carbopol®) used as an about 0.25% solution.
• Adjuvant effects may also be achieved by aggregation of the antigen in the vaccine by heat treatment with temperatures ranging between about 70° to about 101°C for a 30 second to 2-minute period, respectively. Aggregation by reactivating with pepsin treated (Fab) antibodies to albumin, mixture with bacterial cell(s) such as C.
• Fab pepsin treated
• an endotoxin or a lipopolysaccharide component of Gram-negative bacteria emulsion in physiologically acceptable oil vehicles, such as mannide mono-oleate (Aracel A), or emulsion with a 20% solution of a perfluorocarbon (Fluosol-DA®) used as a block substitute, also may be employed.
• physiologically acceptable oil vehicles such as mannide mono-oleate (Aracel A)
• Some adjuvants for example, certain organic molecules obtained from bacteria, act on the host rather than on the antigen.
• An example is MDP, a bacterial peptidoglycan.
• MDP a bacterial peptidoglycan.
• the effects of MDP, as with most adjuvants, are not fully understood, although th einvetnors are now beginning to understand that they activate cells of the innate immune system, e.g. dendritic cells, macrophages, neutrophils, NKT cells, NK cells, etc. MDP stimulates macrophages but also appears to stimulate B cells directly.
• the effects of adjuvants therefore, are not antigen-specific. If they are administered together with a purified antigen, however, they can be used to selectively promote the response to the antigen.
• hemocyanins and hemoerythrins may also be used in the compositions of the present disclosure.
• the use of hemocyanin from keyhole limpet (KLH) is preferred in certain embodiments, although other molluscan and arthropod hemocyanins and hemoerythrins may be employed.
• Various polysaccharide adjuvants may also be used.
• the use of various pneumococcal polysaccharide adjuvants on the antibody responses of mice has been described (Yin et al, 1989).
• Polyamine varieties of polysaccharides are particularly preferred, such as chitin and chitosan, including deacetylated chitin.
• Another group of adjuvants are the muramyl dipeptide (MDP, N- acetylmuramyl-L-alanyl-D-isoglutamine) group of bacterial peptidoglycans.
• MDP muramyl dipeptide
• Derivatives of muramyl dipeptide such as the amino acid derivative threonyl-MDP, and the fatty acid derivative muramyl tripeptide phosphatidylethanolamide (MTPPE
• U.S. Patent 4,950,645 describes a lipophilic disaccharide-tripeptide derivative of muramyl dipeptide which is described for use in artificial liposomes formed from phosphatidyl choline and phosphatidyl glycerol. This is effective in activating human monocytes and destroying tumor cells, but is non-toxic in generally high doses.
• the compounds of U.S. Patent 4,950,645 and PCT Patent Application WO 91/16347, are contemplated for use with cellular carriers and other embodiments of the present disclosure.
• BCG and BCG-cell wall skeleton may also be used as adjuvants, with or without trehalose dimycolate.
• Trehalose dimycolate may be used itself.
• Trehalose dimycolate administration has been shown to correlate with augmented resistance to influenza virus infection in mice (Azuma et al, 1988).
• Trehalose dimycolate may be prepared as described in U.S. Patent 4,579,945.
• BCG is an important clinical tool because of its immunostimulatory properties.
• BCG acts to stimulate the reticuloendothelial system (RES), activates natural killer (NK) cells and increases proliferation of hematopoietic stem cells.
• RES reticuloendothelial system
• NK natural killer
• BCG mycobacteria
• Snapper et al, 1988; Husson et al, 1990; Martin e/ al, 1990 Live BCG is an effective and safe vaccine used worldwide to prevent tuberculosis.
• BCG and other mycobacteria are highly effective adjuvants, and the immune response to mycobacteria has been studied extensively. With nearly 2 billion immunizations, BCG has a long record of safe use in man (Luelmo, 1982; Lotte et al, 1984).
• An exemplary BCG vaccine is sold as TICE BCG (Organon Inc., West Orange, NJ).
• Amphipathic and surface active agents e.g., saponin and derivatives such as QS21 (Cambridge Biotech) form yet another group of adjuvants for use with the immunogens of the present disclosure.
• Nonionic block copolymer surfactants Roskowich et al, 1994
• Oligonucleotides are another useful group of adjuvants (Yamamoto et al, 1988).
• Quil A and lentinen are other adjuvants that may be used in certain embodiments of the present disclosure.
• Another group of adjuvants are the detoxified endotoxins, such as the refined detoxified endotoxin of U.S. Patent 4,866,034. These refined detoxified endotoxins are effective in producing adjuvant responses in mammals.
• the detoxified endotoxins may be combined with other adjuvants to prepare multi-adjuvant-incorporated cells.
• combination of detoxified endotoxins with trehalose dimycolate is particularly contemplated, as described in U.S. Patent 4,435,386.
• Combinations of detoxified endotoxins with trehalose dimycolate and endotoxic glycolipids is also contemplated (U.S.
• Patent 4,505,899 is combination of detoxified endotoxins with cCWS or CWS and trehalose dimycolate, as described in U.S. Patents 4,436,727, 4,436,728 and 4,505,900. Combinations of just CWS and trehalose dimycolate, without detoxified endotoxins, are also envisioned to be useful, as described in U.S. Patent 4,520,019.
• adjuvants that can be conjugated to vaccines in accordance with this disclosure and which are approved for human vs experimental use. These include alkyl lysophosphilipids (ALP); BCG; and biotin (including biotinylated derivatives) among others.
• ALP alkyl lysophosphilipids
• BCG BCG
• biotin including biotinylated derivatives
• Certain adjuvants particularly contemplated for use are the teichoic acids from Gram " bacterial cells. These include the lipoteichoic acids (LTA), ribitol teichoic acids (RTA) and glycerol teichoic acid (GTA).
• LTA lipoteichoic acids
• RTA ribitol teichoic acids
• GTA glycerol teichoic acid
• Adjuvants may be encoded by a nucleic acid (e.g., DNA or RNA). It is contemplated that such adjuvants may be also be encoded in a nucleic acid (e.g. , an expression vector) encoding the antigen, or in a separate vector or other construct. Nucleic acids encoding the adjuvants can be delivered directly, such as for example with lipids or liposomes.
• BRM Biological Response Modifiers
• BRM co-administeredministered with BRM, which have been shown to upregulate T cell immunity or downregulate suppressor cell activity.
• BRMs include, but are not limited to, cimetidine (CIM; 1200 mg/d) (Smith/Kline, PA); low-dose cyclophosphamide (CYP; 300 mg/m 2 ) (Johnson/ Mead, NJ), cytokines such as - interferon, IL-2, or IL-12 or genes encoding proteins involved in immune helper functions, such as B-7.
• CCM cimetidine
• CYP low-dose cyclophosphamide
• cytokines such as - interferon, IL-2, or IL-12 or genes encoding proteins involved in immune helper functions, such as B-7.
• Additional biological response modifiers include those described in Gupta and Kanodia, 2002 and Bisht, et al , 2010, both of which are incorporated herein by reference.
• Chemokines nucleic acids that encode for chemokines, and/or cells that express such also may be used as vaccine components.
• Chemokines generally act as chemoattractants to recruit immune effector cells to the site of chemokine expression. It may be advantageous to express a particular chemokine coding sequence in combination with, for example, a cytokine coding sequence, to enhance the recruitment of other immune system components to the site of treatment.
• chemokines include, for example, RANTES, MCAF, MIPl-a, MIPl- ⁇ , IP- 10 and combinations thereof.
• cytokines are also known to have chemoattractant effects and could also be classified under the term chemokines.
• the vaccine composition described herein may be chemically coupled to a carrier or recombinantly expressed with a immunogenic carrier peptide or polypetide (e.g., a antigen-carrier fusion peptide or polypeptide) to enhance an immune reaction.
• a immunogenic carrier peptide or polypetide e.g., a antigen-carrier fusion peptide or polypeptide
• exemplary and preferred immunogenic carrier amino acid sequences include hepatitis B surface antigen (HBSA), tetanus toxoid (TT), keyhole limpet hemocyanin (KLH) and BSA.
• TT would be advantageous since it is already an approved protein vaccine.
• other albumins such as OVA, mouse serum albumin or rabbit serum albumin also can be used as immunogenic carrier proteins.
• Means for conjugating a polypeptide or peptide to an immunogenic carrier protein are well known in the art and include, for example, glutaraldehyde, m-maleimidobenzoyl-N- hydroxysuccinimide ester, carbodiimide and bis-biazotized benzidine.
• compositions in a form appropriate for the intended application.
• such formulation with the compounds of the present disclosure is contemplated.
• this will entail preparing compositions that are essentially free of pyrogens, as well as other impurities that could be harmful to humans or animals.
• compositions of the present disclosure comprise an effective amount of the vaccine composition, dissolved or dispersed in a pharmaceutically acceptable carrier or aqueous medium. Such compositions also are referred to as inocula.
• pharmaceutically or pharmacologically acceptable refers to molecular entities and compositions that do not produce adverse, allergic, or other untoward reactions when administered to an animal or a human.
• pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like.
• the use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the compositions of the present disclosure, its use in therapeutic compositions is contemplated. Supplementary active ingredients also can be incorporated into the compositions.
• compositions of the present disclosure may include classic pharmaceutical preparations. Administration of these compositions according to the present disclosure will be via any common route so long as the target tissue is available via that route. Such routes include oral, nasal, buccal, rectal, vaginal or topical route. Alternatively, administration may be by orthotopic, intradermal, subcutaneous, intramuscular, intratumoral, intraperitoneal, or intravenous injection. Such compositions would normally be administered as pharmaceutically acceptable compositions, described supra.
• pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like.
• the use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
• the vaccine composition described herein may be incorporated with excipients and used in the form of non-ingestible mouthwashes and dentifrices.
• a mouthwash may be prepared incorporating the active ingredient in the required amount in an appropriate solvent, such as a sodium borate solution (Dobell's Solution).
• the active ingredient may be incorporated into an antiseptic wash containing sodium borate, glycerin and potassium bicarbonate.
• the active ingredient may also be dispersed in dentifrices, including: gels, pastes, powders and slurries.
• the active ingredient may be added in a therapeutically effective amount to a paste dentifrice that may include water, binders, abrasives, flavoring agents, foaming agents, and humectants.
• a paste dentifrice may include water, binders, abrasives, flavoring agents, foaming agents, and humectants.
• Injection may be by syringe or any other method used for injection of a solution, as long as the agent can pass through the particular gauge of needle required for injection.
• a novel needleless injection system has been described (U.S. Patent 5,846,233) having a nozzle defining an ampule chamber for holding the solution and an energy device for pushing the solution out of the nozzle to the site of delivery.
• Solutions of the active compounds as free base or pharmacologically acceptable salts may be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose.
• Dispersions may also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
• the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions (U.S. Patent 5,466,468, specifically incorporated herein by reference in its entirety).
• the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and/or vegetable oils.
• a coating such as lecithin
• surfactants for example
• the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
• isotonic agents for example, sugars or sodium chloride.
• Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
• aqueous solutions for parenteral administration in an aqueous solution, for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
• aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous, and intraperitoneal administration.
• sterile aqueous media that can be employed will be known to those of skill in the art in light of the present disclosure.
• one dosage may be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 mL of hypodermolysis fluid or injected at the proposed site of infusion, (see for example, "Remington's Pharmaceutical Sciences," 15th Edition, pages 1035-1038 and 1570-1580). Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject. Moreover, for human administration, preparations should meet sterility, pyrogenicity, and general safety and purity standards as required by FDA Office of Biologies standards.
• Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various other ingredients enumerated above, as required, followed by filtered sterilization.
• dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
• the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
• the compositions disclosed herein may be formulated in a neutral or salt form.
• Pharmaceutically-acceptable salts include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like.
• solutions Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective.
• the formulations are easily administered in a variety of dosage forms such as injectable solutions, drug release capsules and the like.
• buffer or diluent includes any and all solvents, dispersion media, vehicles, coatings, diluents, excipients, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, solutions, suspensions, colloids, and the like.
• dispersion media includes any and all solvents, dispersion media, vehicles, coatings, diluents, excipients, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, solutions, suspensions, colloids, and the like.
• the use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
• phrases "pharmaceutically-acceptable” or “pharmacologically-acceptable” refer to molecular entities and compositions that do not produce an allergic or similar untoward reaction when administered to a human.
• the preparation of an aqueous composition that contains a protein as an active ingredient is well understood in the art.
• such compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection can also be prepared.
• compositions that may be used in treating cancer in a subject are disclosed herein.
• the compositions described above are preferably administered to a mammal (e.g. , rodent, human, non-human primates, canine, bovine, ovine, equine, feline, etc.) in an effective amount, that is, an amount capable of producing a desirable result in a treated subject (e.g. , causing apoptosis of cancerous cells).
• Toxicity and therapeutic efficacy of the compositions utilized in methods of the disclosure can be determined by standard pharmaceutical procedures.
• dosage for any one animal depends on many factors, including the subject's size, body surface area, body weight, age, the particular composition to be administered, time and route of administration, general health, the clinical symptoms of the infection or cancer and other drugs being administered concurrently.
• a composition as described herein is typically administered at a dosage that inhibits the growth or proliferation of a bacterial cell, inhibits the growth of a biofilm, or induces death of cancerous cells (e.g. , induces apoptosis of a cancer cell), as assayed by identifying a reduction in hematological parameters (complete blood count - CBC), or cancer cell growth or proliferation.
• amounts of the meayamycin, thailanstatin A methyl ester, and analogs thereof used to induce apoptosis of the cancer cells is calculated to be from about 0.01 mg to about 10,000 mg/day. In some embodiments, the amount is from about 1 mg to about 1,000 mg/day. In some embodiments, these dosings may be reduced or increased based upon the biological factors of a particular patient such as increased or decreased metabolic breakdown of the drug or decreased uptake by the digestive tract if administered orally. Addtionally, the vaccine compositions described herein may be more efficacious and thus a smaller dose is required to achieve a similar effect. Such a dose is typically administered once a day for a few weeks or until sufficient reducing in cancer cells has been achieved.
• the therapeutic methods of the disclosure in general include administration of a therapeutically effective amount of the compositions described herein to a subject in need thereof, including a mammal, particularly a human.
• Such treatment will be suitably administered to subjects, particularly humans, suffering from, having, susceptible to, or at risk for a disease, disorder, or symptom thereof. Determination of those subjects "at risk” can be made by any objective or subjective determination by a diagnostic test or opinion of a subject or health care provider (e.g., genetic test, enzyme or protein marker, marker (as defined herein), family history, and the like).
• the disclosure provides a method of monitoring treatment progress.
• the method includes the step of determining a level of changes in hematological parameters and/or cancer stem cell (CSC) analysis with cell surface proteins as diagnostic markers (which can include, for example, but are not limited to CD34, CD38, CD90, and CD 117) or diagnostic measurement (e.g., screen, assay) in a subject suffering from or susceptible to a disorder or symptoms thereof associated with cancer (e.g., leukemia) in which the subject has been administered a therapeutic amount of a composition as described herein.
• CSC cancer stem cell
• diagnostic measurement e.g., screen, assay
• the level of marker determined in the method can be compared to known levels of marker in either healthy normal controls or in other afflicted patients to establish the subject's disease status.
• a second level of marker in the subject is determined at a time point later than the determination of the first level, and the two levels are compared to monitor the course of disease or the efficacy of the therapy.
• a pre-treatment level of marker in the subject is determined prior to beginning treatment according to the methods described herein; this pre-treatment level of marker can then be compared to the level of marker in the subject after the treatment commences, to determine the efficacy of the treatment.
• the vaccine compositions described herein may be used in combination therapies with one or more additional therapies or a compound which mitigates one or more of the side effects experienced by the patient. It is common in the field of medicine to combine therapeutic modalities. The following is a general discussion of therapies that may be used in conjunction with the therapies of the present disclosure.
• compositions and at least one other therapy would be provided in a combined amount effective to achieve a reduction in one or more disease parameter.
• This process may involve contacting the cells/subjects with the both agents/therapies at the same time, e.g., using a single composition or pharmacological formulation that includes both agents, or by contacting the cell/subject with two distinct compositions or formulations, at the same time, wherein one composition includes the vaccine compositions and the other includes the other agent.
• the vaccine compositions described herein may precede or follow the other treatment by intervals ranging from minutes to weeks.
• each of these therapies may be administered two or more times either in combination or individually.
• a first therapy may be administered with a second therapy and then the first therapy may be administered a second time either alone or again in combination with the second therapy.
• chemotherapeutic agent refers to the use of drugs to treat cancer.
• a “chemotherapeutic agent” is used to connote a compound or composition that is administered in the treatment of cancer. These agents or drugs are categorized by their mode of activity within a cell, for example, whether and at what stage they affect the cell cycle. Alternatively, an agent may be characterized based on its ability to directly cross-link DNA, to intercalate into DNA, or to induce chromosomal and mitotic aberrations by affecting nucleic acid synthesis. Most chemotherapeutic agents fall into the following categories: alkylating agents, antimetabolites, antitumor antibiotics, mitotic inhibitors, and nitrosoureas.
• chemotherapeutic agents include alkylating agents such as thiotepa and cyclosphosphamide; alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide, triethiylenethiophosphoramide and trimethylolomelamine; acetogenins (especially bullatacin and bullatacinone); a camptothecin (including the synthetic analog topotecan); bryostatin; cally statin; CC-1065 (including its adozelesin, carzelesin and bizelesin synthetic analogs); cryptophycins (particularly cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin (including the synthetic analogs
• paclitaxel and docetaxel paclitaxel and docetaxel; chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum coordination complexes such as cisplatin, oxaliplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitoxantrone; vincristine; vinorelbine; novantrone; teniposide; edatrexate; daunomycin; aminopterin; xeloda; ibandronate; irinotecan (e.g.
• topoisomerase inhibitor RFS 2000 difluorometlhylomithine (DMFO); retinoids such as retinoic acid; capecitabine; cisplatin (CDDP), carboplatin, procarbazine, mechlorethamine, cyclophosphamide, camptothecin, ifosfamide, melphalan, chlorambucil, busulfan, nitrosurea, dactinomycin, daunorubicin, doxorubicin, bleomycin, plicomycin, mitomycin, etoposide (VP 16), tamoxifen, raloxifene, estrogen receptor binding agents, taxol, paclitaxel, docetaxel, gemcitabien, navelbine, farnesyl-protein tansferase inhibitors, transplatinum, 5-fluorouracil, vincristin, vinblastin and methotrexate and pharmaceutically acceptable salts, acids or
• Radiotherapy also called radiation therapy, is the treatment of cancer and other diseases with ionizing radiation. Ionizing radiation deposits energy that injures or destroys cells in the area being treated by damaging their genetic material, making it impossible for these cells to continue to grow. Although radiation damages both cancer cells and normal cells, the latter are able to repair themselves and function properly.
• Radiation therapy used according to the present disclosure may include, but is not limited to, the use of ⁇ -rays, X-rays, and/or the directed delivery of radioisotopes to tumor cells.
• DNA damaging factors are also contemplated such as microwaves and UV-irradiation. It is most likely that all of these factors induce a broad range of damage on DNA, on the precursors of DNA, on the replication and repair of DNA, and on the assembly and maintenance of chromosomes.
• Dosage ranges for X-rays range from daily doses of 50 to 200 roentgens for prolonged periods of time (3 to 4 wk), to single doses of 2000 to 6000 roentgens.
• Dosage ranges for radioisotopes vary widely, and depend on the half-life of the isotope, the strength and type of radiation emitted, and the uptake by the neoplastic cells.
• Radiotherapy may comprise the use of radiolabeled antibodies to deliver doses of radiation directly to the cancer site (radioimmunotherapy).
• Antibodies are highly specific proteins that are made by the body in response to the presence of antigens (substances recognized as foreign by the immune system). Some tumor cells contain specific antigens that trigger the production of tumor-specific antibodies. Large quantities of these antibodies can be made in the laboratory and attached to radioactive substances (a process known as radiolabeling). Once injected into the body, the antibodies actively seek out the cancer cells, which are destroyed by the cell-killing (cytotoxic) action of the radiation. This approach can minimize the risk of radiation damage to healthy cells.
• Conformal radiotherapy uses the same radiotherapy machine, a linear accelerator, as the normal radiotherapy treatment but metal blocks are placed in the path of the x-ray beam to alter its shape to match that of the cancer. This ensures that a higher radiation dose is given to the tumor. Healthy surrounding cells and nearby structures receive a lower dose of radiation, so the possibility of side effects is reduced.
• a device called a multi-leaf collimator has been developed and may be used as an alternative to the metal blocks.
• the multi-leaf collimator consists of a number of metal sheets which are fixed to the linear accelerator. Each layer can be adjusted so that the radiotherapy beams can be shaped to the treatment area without the need for metal blocks. Precise positioning of the radiotherapy machine is very important for conformal radiotherapy treatment and a special scanning machine may be used to check the position of internal organs at the beginning of each treatment.
• High-resolution intensity modulated radiotherapy also uses a multi-leaf collimator. During this treatment the layers of the multi-leaf collimator are moved while the treatment is being given. This method is likely to achieve even more precise shaping of the treatment beams and allows the dose of radiotherapy to be constant over the whole treatment area.
• Radiosensitizers make the tumor cells more likely to be damaged, and radioprotectors protect normal tissues from the effects of radiation.
• Hyperthermia the use of heat, is also being studied for its effectiveness in sensitizing tissue to radiation.
• immunotherapeutics In the context of cancer treatment, immunotherapeutics, generally, rely on the use of immune effector cells and molecules to target and destroy cancer cells.
• Trastuzumab (HerceptinTM) is such an example.
• the immune effector may be, for example, an antibody specific for some marker on the surface of a tumor cell.
• the antibody alone may serve as an effector of therapy or it may recruit other cells to actually affect cell killing.
• the antibody also may be conjugated to a drug or toxin (chemotherapeutic, radionuclide, ricin A chain, cholera toxin, pertussis toxin, etc.) and serve merely as a targeting agent.
• toxin chemotherapeutic, radionuclide, ricin A chain, cholera toxin, pertussis toxin, etc.
• the effector may be a lymphocyte carrying a surface molecule that interacts, either directly or indirectly, with a tumor cell target.
• Various effector cells include cytotoxic T cells and NK cells.
• the combination of therapeutic modalities, i.e., direct cytotoxic activity and inhibition or reduction of ErbB2 would provide therapeutic benefit in the treatment of ErbB2 overexpressing cancers.
• the tumor cell In one aspect of immunotherapy, the tumor cell must bear some marker that is amenable to targeting, i.e., is not present on the majority of other cells. Many tumor markers exist and any of these may be suitable for targeting in the context of the present disclosure.
• Common tumor markers include carcinoembryonic antigen, prostate specific antigen, urinary tumor associated antigen, fetal antigen, tyrosinase (p97), gp68, TAG-72, HMFG, Sialyl Lewis Antigen, MucA, MucB, PLAP, estrogen receptor, laminin receptor, erb B and pi 55.
• An alternative aspect of immunotherapy is to combine anticancer effects with immune stimulatory effects.
• Immune stimulating molecules also exist including: cytokines such as IL-2, IL-4, IL-12, GM-CSF, ⁇ -IFN, chemokines such as MIP-1, MCP-1, IL-8 and growth factors such as FLT3 ligand.
• immune stimulating molecules either as proteins or using gene delivery in combination with a tumor suppressor has been shown to enhance antitumor effects (Ju et al , 2000).
• antibodies against any of these compounds may be used to target the anti-cancer agents discussed herein.
• immunotherapies currently under investigation or in use are immune adjuvants e.g. , Mycobacterium bovis, Plasmodium falciparum, dinitrochlorobenzene and aromatic compounds (U.S. Patents 5,801,005 and 5,739,169; Hui and Hashimoto, 1998; Christodoulides et al, 1998), cytokine therapy, e.g.
• interferons ⁇ , ⁇ , and ⁇ ; IL-1, GM-CSF and TNF (Bukowski et al, 1998; Davidson et al , 1998; Hellstrand et al , 1998) gene therapy, e.g., TNF, IL-1, IL-2, p53 (Qin et al, 1998; Austin-Ward and Villaseca, 1998; U.S. Patents 5,830,880 and 5,846,945) and monoclonal antibodies, e.g., anti-ganglioside GM2, anti-HER- 2, anti-pl85 (Pietras et al, 1998; Hanibuchi et al, 1998; U.S. Patent 5,824,311). It is contemplated that one or more anti-cancer therapies may be employed with the gene silencing therapies described herein.
• an antigenic peptide, polypeptide or protein, or an autologous or allogenic tumor cell composition or "vaccine” is administered, generally with a distinct bacterial adjuvant (Ravindranath and Morton, 1991; Morton et al , 1992; Mitchell et al , 1990; Mitchell et al, 1993).
• the patient's circulating lymphocytes, or tumor infiltrated lymphocytes are isolated in vitro, activated by lymphokines such as IL-2 or transduced with genes for tumor necrosis, and readministered (Rosenberg et al, 1988; 1989).
• Curative surgery is a cancer treatment that may be used in conjunction with other therapies, such as the treatment of the present disclosure, chemotherapy, radiotherapy, hormonal therapy, gene therapy, immunotherapy and/or alternative therapies.
• Curative surgery includes resection in which all or part of cancerous tissue is physically removed, excised, and/or destroyed.
• Tumor resection refers to physical removal of at least part of a tumor.
• treatment by surgery includes laser surgery, cryosurgery, electrosurgery, and microscopically controlled surgery (Mohs' surgery). It is further contemplated that the present disclosure may be used in conjunction with removal of superficial cancers, precancers, or incidental amounts of normal tissue.
• a cavity may be formed in the body.
• Treatment may be accomplished by perfusion, direct injection or local application of the area with an additional anti-cancer therapy.
• Such treatment may be repeated, for example, every 1, 2, 3, 4, 5, 6, or 7 days, or every 1, 2, 3, 4, and 5 weeks or every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months.
• These treatments may be of varying dosages as well.
• an adjuvant treatment with a compound of the present disclosure is believe to be particularly efficacious in reducing the reoccurance of the tumor.
• the compounds of the present disclosure can also be used in a neoadjuvant setting.
• agents may be used with the present disclosure.
• additional agents include immunomodulatory agents, agents that affect the upregulation of cell surface receptors and GAP junctions, cytostatic and differentiation agents, inhibitors of cell adhesion, agents that increase the sensitivity of the hyperproliferative cells to apoptotic inducers, or other biological agents.
• Immunomodulatory agents include tumor necrosis factor; interferon alpha, beta, and gamma; IL-2 and other cytokines; F42K and other cytokine analogs; or MIP-1, ⁇ - ⁇ , MCP-1, RANTES, and other chemokines.
• cell surface receptors or their ligands such as Fas/Fas ligand, DR4 or DR5/TRAIL (Apo-2 ligand) would potentiate the apoptotic inducing abilities of the present disclosure by establishment of an autocrine or paracrine effect on hyperproliferative cells. Increases intercellular signaling by elevating the number of GAP junctions would increase the anti-hyperproliferative effects on the neighboring hyperproliferative cell population.
• cytostatic or differentiation agents may be used in combination with the present disclosure to improve the anti-hyerproliferative efficacy of the treatments.
• Inhibitors of cell adhesion are contemplated to improve the efficacy of the present disclosure.
• cell adhesion inhibitors are focal adhesion kinase (FAKs) inhibitors and Lovastatin. It is further contemplated that other agents that increase the sensitivity of a hyperproliferative cell to apoptosis, such as the antibody c225, could be used in combination with the present disclosure to improve the treatment efficacy.
• FAKs focal adhesion kinase
• Lovastatin Lovastatin
• hyperthermia is a procedure in which a patient's tissue is exposed to high temperatures (up to 106°F).
• External or internal heating devices may be involved in the application of local, regional, or whole-body hyperthermia.
• Local hyperthermia involves the application of heat to a small area, such as a tumor. Heat may be generated externally with high-frequency waves targeting a tumor from a device outside the body. Internal heat may involve a sterile probe, including thin, heated wires or hollow tubes filled with warm water, implanted microwave antennae, or radiofrequency electrodes.
• a patient's organ or a limb is heated for regional therapy, which is accomplished using devices that produce high energy, such as magnets.
• some of the patient's blood may be removed and heated before being perfused into an area that will be internally heated.
• Whole-body heating may also be implemented in cases where cancer has spread throughout the body. Warm- water blankets, hot wax, inductive coils, and thermal chambers may be used for this purpose.
• antibiotics are drugs which may be used to treat a bacterial infection through either inhibiting the growth of bacteria or killing bacteria. Without being bound by theory, it is believed that antibiotics can be classified into two major classes: bactericidal agents that kill bacteria or bacteriostatic agents that slow down or prevent the growth of bacteria.
• antibiotics can fall into a wide range of classes.
• the compounds of the present disclosure may be used in conjunction with another antibiotic.
• the compounds may be used in conjunction with a narrow spectrum antibiotic which targets a specific bacteria type.
• bactericidal antibiotics include penicillin, cephalosporin, polymyxin, rifamycin, lipiarmycin, quinolones, and sulfonamides.
• bacteriostatic antibiotics include macrolides, lincosamides, or tetracyclines.
• the antibiotic is an aminoglycoside such as kanamycin and streptomycin, an ansamycin such as rifaximin and geldanamycin, a carbacephem such as loracarbef, a carbapenem such as ertapenem, imipenem, a cephalosporin such as cephalexin, cefixime, cefepime, and ceftobiprole, a glycopeptide such as vancomycin or teicoplanin, a lincosamide such as lincomycin and clindamycin, a lipopeptide such as daptomycin, a macrolide such as clarithromycin, spiramycin, azithromycin, and telithromycin, a monobactam such as aztreonam, a nitrofuran such as furazolidone and nitrofurantoin, an oxazolidonones such as linezolid, a penicillin such as amoxicillin,
• the compounds could be combined with a drug which acts against mycobacteria such as cycloserine, capreomycin, ethionamide, rifampicin, rifabutin, rifapentine, and streptomycin.
• a drug which acts against mycobacteria such as cycloserine, capreomycin, ethionamide, rifampicin, rifabutin, rifapentine, and streptomycin.
• Other antibiotics that are contemplated for combination therapies may include arsphenamine, chloramphenicol, fosfomycin, fusidic acid, metronidazole, mupirocin, platensimycin, quinupristin, dalfopristin, thiamphenicol, tigecycline, tinidazole, or trimethoprim.
• antiviral or "antiviral agents” are drugs which may be used to treat a viral infection.
• antiviral agents act via two major mechanisms: preventing viral entry into the cell and inhibiting viral synthesis.
• viral replication can be inhibited by using agents that mimic either the virus-associated proteins and thus block the cellular receptors or using agents that mimic the cellular receptors and thus block the virus-associated proteins.
• agents which cause an uncoating of the virus can also be used as antiviral agents.
• the second mechanism of viral inhibition is preventing or interrupting viral synthesis.
• Such drugs can target different proteins associated with the replication of viral DNA including reverse transcriptase, integrase, transcription factors, or ribozymes.
• the therapeutic agent interrupts translation by acting as an antisense DNA strain, inhibiting the formation of protein processing or assembly, or acting as virus protease inhibitors.
• an anti-viral agent could additionally inhibit the release of the virus after viral production in the cell.
• anti-viral agents could modulate the bodies own immune system to fight a viral infection. Without being bound by theory, the anti-viral agent which stimulates the immune system may be used with a wide variety of viral infections.
• the present disclosure provides methods of using the disclosed compounds in a combination therapy with an anti-viral agent as described above.
• the anti-viral agent is abacavir, aciclovir, acyclovir, adefovir, amantadine, amprenavir, ampligen, arbidol, atazanavir, atripla, balavir, boceprevirertet, cidofovir, combivir, dolutegravir, daruavir, delavirdine, didanosine, docosanol, edoxudine, efavirenz, emtricitabine, enfuvirtide, entecavir, ecoliever, famciclovir, fomivirsen, fosamprenavir, foscamet, fosfonet, ganciclovir, ibacitabine, imunovir, idoxuridine, imiquimod, indin
• the anti-viral agents is an anti-retroviral, a fusion inhibitor, an integrase inhibitor, an interferon, a nucleoside analogues, a protease inhibitor, a reverse transcriptase inhibitor, a synergistic enhancer, or a natural product such as tea tree oil.
• the symbol "- ⁇ ” means a single bond where the group attached to the thick end of the wedge is “out of the page.”
• the symbol “”W “ means a single bond where the group attached to the thick end of the wedge is “into the page”.
• the symbol " > ⁇ " means a single bond where the geometry around a double bond (e.g. , either E or Z) is undefined. Both options, as well as combinations thereof are therefore intended. Any undefined valency on an atom of a structure shown in this application implicitly represents a hydrogen atom bonded to that atom. A bold dot on a carbon atom indicates that the hydrogen attached to that carbon is oriented out of the plane of the paper.
• R may replace any hydrogen atom attached to any of the ring atoms, including a depicted, implied, or expressly defined hydrogen, so long as a stable structure is formed.
• R may replace any hydrogen atom attached to any of the ring atoms, including a depicted, implied, or expressly defined hydrogen, so long as a stable structure is formed.
• R may replace any hydrogen attached to any of the ring atoms of either of the fused rings unless specified otherwise.
• Replaceable hydrogens include depicted hydrogens (e.g., the hydrogen attached to the nitrogen in the formula above), implied hydrogens (e.g. , a hydrogen of the formula above that is not shown but understood to be present), expressly defined hydrogens, and optional hydrogens whose presence depends on the identity of a ring atom (e.g., a hydrogen attached to group X, when X equals -CH-), so long as a stable structure is formed.
• R may reside on either the 5-membered or the 6- membered ring of the fused ring system.
• C ⁇ n defines the maximum number (n) of carbon atoms that can be in the group/class, with the minimum number as small as possible for the group/class in question, e.g., it is understood that the minimum number of carbon atoms in the group “alkenyl(c ⁇ 8)” or the class “alkene(c ⁇ 8)” is two. Compare with “alkoxy(c ⁇ io)", which designates alkoxy groups having from 1 to 10 carbon atoms. "Cn-n”' defines both the minimum (n) and maximum number ( ⁇ ') of carbon atoms in the group. Thus, "alkyl(C2-io)” designates those alkyl groups having from 2 to 10 carbon atoms.
• saturated when used to modify a compound or chemical group means the compound or chemical group has no carbon-carbon double and no carbon-carbon triple bonds, except as noted below.
• the term when used to modify an atom, it means that the atom is not part of any double or triple bond.
• substituted versions of saturated groups one or more carbon oxygen double bond or a carbon nitrogen double bond may be present. And when such a bond is present, then carbon-carbon double bonds that may occur as part of keto-enol tautomerism or imine/enamine tautomerism are not precluded.
• saturated when used to modify a solution of a substance, it means that no more of that substance can dissolve in that solution.
• aliphatic when used without the "substituted” modifier signifies that the compound or chemical group so modified is an acyclic or cyclic, but non- aromatic hydrocarbon compound or group.
• the carbon atoms can be joined together in straight chains, branched chains, or non-aromatic rings (alicyclic).
• Aliphatic compounds/groups can be saturated, that is joined by single carbon-carbon bonds (alkanes/alkyl), or unsaturated, with one or more carbon-carbon double bonds (alkenes/alkenyl) or with one or more carbon-carbon triple bonds (alkynes/alkynyl).
• aromatic when used to modify a compound or a chemical group refers to a planar unsaturated ring of atoms with An +2 electrons in a fully conjugated cyclic ⁇ system.
• alkyl when used without the "substituted” modifier refers to a monovalent saturated aliphatic group with a carbon atom as the point of attachment, a linear or branched acyclic structure, and no atoms other than carbon and hydrogen.
• alkanediyl when used without the "substituted” modifier refers to a divalent saturated aliphatic group, with one or two saturated carbon atom(s) as the point(s) of attachment, a linear or branched acyclic structure, no carbon-carbon double or triple bonds, and no atoms other than carbon and hydrogen.
• the groups -CH2- (methylene), -CH2CH2-, -CH 2 C(CH 3 ) 2 CH 2 -, and -CH2CH2CH2- are non- limiting examples of alkanediyl groups.
• An "alkane” refers to the class of compounds having the formula H-R, wherein R is alkyl as this term is defined above.
• one or more hydrogen atom has been independently replaced by -OH, -F, -CI, -Br, -I, -NH 2 , -NO2, -CO2H, -C0 2 CH 3 , -CN, -SH, -OCH 3 , -OCH 2 CH 3 , -C(0)CH 3 , -NHCH 3 , -NHCH 2 CH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , -C(0)N(CH 3 ) 2 , -OC(0)CH 3 , -NHC(0)CH 3 , -S(0) 2 OH, or -S(0) 2 NH 2 .
• haloalkyl is a subset of substituted alkyl, in which the hydrogen atom replacement is limited to halo (i.e.
• -F, -CI, -Br, or -I such that no other atoms aside from carbon, hydrogen and halogen are present.
• -CH2CI is a non-limiting example of a haloalkyl.
• fluoroalkyl is a subset of substituted alkyl, in which the hydrogen atom replacement is limited to fluoro such that no other atoms aside from carbon, hydrogen and fluorine are present.
• the groups -CH2F, -CF3, and -CH2CF 3 are non-limiting examples of fluoroalkyl groups.
• cycloalkyl when used without the “substituted” modifier refers to a monovalent saturated aliphatic group with a carbon atom as the point of attachment, said carbon atom forming part of one or more non-aromatic ring structures, no carbon-carbon double or triple bonds, and no atoms other than carbon and hydrogen.
• Non-limiting examples include: -CH(CH2)2 (cyclopropyl), cyclobutyl, cyclopentyl, or cyclohexyl (Cy).
• cycloalkanediyl when used without the “substituted” modifier refers to a divalent saturated aliphatic group with two carbon atoms as points of attachment, no carbon double or triple bonds, and no atoms other than carbon and hydrogen.
• the group is a non-limiting example of cycloalkanediyl group.
• a "cycloalkane” refers to the class of compounds having the formula H-R, wherein R is cycloalkyl as this term is defined above.
• heterocycloalkyl when used without the "substituted” modifier refers to a monovalent non-aromatic group with a carbon atom or nitrogen atom as the point of attachment, said carbon atom or nitrogen atom forming part of one or more non-aromatic ring structures wherein at least one of the ring atoms is nitrogen, oxygen or sulfur, and wherein the heterocycloalkyl group consists of no atoms other than carbon, hydrogen, nitrogen, oxygen and sulfur. If more than one ring is present, the rings may be fused or unfused. As used herein, the term does not preclude the presence of one or more alkyl groups (carbon number limitation permitting) attached to the ring or ring system.
• heterocycloalkyl groups include aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydrofuranyl, tetrahydrothiofuranyl, tetrahydropyranyl, pyranyl, oxiranyl, and oxetanyl.
• N-heterocycloalkyl refers to a heterocycloalkyl group with a nitrogen atom as the point of attachment.
• N-pyrrolidinyl is an example of such a group.
• substituted one or more hydrogen atom has been independently replaced by -OH, -F, -CI, -Br, -I, - ⁇ 2, - ⁇ 2, -CO2H, -CO2CH3, -CN, -SH, -OCH3, -OCH2CH3, -C(0)CH 3 , -NHCH3, -NHCH2CH3, -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , -C(0)N(CH 3 ) 2 , -OC(0)CH 3 , -NHC(0)CH 3 , -S(0) 2 OH, or -S(0) 2 NH 2 .
• acyl when used without the “substituted” modifier refers to the group -C(0)R, in which R is a hydrogen, alkyl, cycloalkyl, or aryl as those terms are defined above.
• the groups, -CHO, -C(0)CH 3 (acetyl, Ac), -C(0)CH 2 CH 3 , -C(0)CH(CH 3 ) 2 , -C(0)CH(CH 2 ) 2 , -C(0)C6H5, and -C(0)C6H4CH 3 are non-limiting examples of acyl groups.
• a “thioacyl” is defined in an analogous manner, except that the oxygen atom of the group -C(0)R has been replaced with a sulfur atom, -C(S)R.
• aldehyde corresponds to an alkyl group, as defined above, attached to a -CHO group.
• one or more hydrogen atom (including a hydrogen atom directly attached to the carbon atom of the carbonyl or thiocarbonyl group, if any) has been independently replaced by -OH, -F, -CI, -Br, -I, -NH 2 , -NO2, -C0 2 H, -C0 2 CH 3 , -CN, -SH, -OCH 3 , -OCH 2 CH 3 , -C(0)CH 3 , -NHCH 3 , -NHCH 2 CH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , -C(0)N(CH 3 ) 2 , -OC(0)CH 3 , -NHC(0)CH 3 , -S(0) 2 OH, or -S(0) 2 NH 2 .
• the groups, -C(0)CH 2 CF 3 , -C0 2 H (carboxyl), -C0 2 CH 3 (methylcarboxyl), -C0 2 CH 2 CH 3 , -C(0)NH 2 (carbamoyl), and -CON(CH 3 ) 2 are non-limiting examples of substituted acyl groups.
• alkoxy when used without the "substituted” modifier refers to the group -OR, in which R is an alkyl, as that term is defined above.
• Non-limiting examples include: -OCH 3 (methoxy), -OCH 2 CH 3 (ethoxy), -OCH 2 CH 2 CH 3 , -OCH(CH 3 ) 2 (isopropoxy), -OC(CH 3 ) 3 (fert-butoxy), -OCH(CH 2 ) 2 , -O-cyclopentyl, and -O-cyclohexyl.
• cycloalkoxy when used without the “substituted” modifier, refers to groups, defined as -OR, in which R is cycloalkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heterocycloalkyl, and acyl, respectively.
• alkoxydiyl refers to the divalent group -O-alkanediyl-, -O-alkanediyl-0-, or -alkanediyl-O-alkanediyl-
• alkylthio and acylthio when used without the "substituted” modifier refers to the group -SR, in which R is an alkyl and acyl, respectively.
• alcohol corresponds to an alkane, as defined above, wherein at least one of the hydrogen atoms has been replaced with a hydroxy group.
• ether corresponds to an alkane, as defined above, wherein at least one of the hydrogen atoms has been replaced with an alkoxy group.
• substituted one or more hydrogen atom has been independently replaced by -OH, -F, -CI, -Br, -I, -NH 2 , -NO2, -CO2H, -CO2CH3, -CN, -SH, -OCH3, -OCH2CH3, -C(0)CH 3 , -NHCH3, -NHCH2CH3, -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , -C(0)N(CH 3 )2, -OC(0)CH 3 , -NHC(0)CH 3 , -S(0) 2 OH, or -S(0) 2 NH 2 .
• alkylamino when used without the "substituted” modifier refers to the group -NHR, in which R is an alkyl, as that term is defined above. Non-limiting examples include: -NHCH3 and -NHCH2CH3.
• dialkylamino when used without the "substituted” modifier refers to the group -NRR', in which R and R' can be the same or different alkyl groups, or R and R' can be taken together to represent an alkanediyl.
• dialkylamino groups include: -N(CH3)2 and -N(CH3)(CH2CH3).
• cycloalkylamino when used without the “substituted” modifier, refers to groups, defined as -NHR, in which R is cycloalkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heterocycloalkyl, alkoxy, and alkylsulfonyl, respectively.
• R is cycloalkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heterocycloalkyl, alkoxy, and alkylsulfonyl, respectively.
• a non-limiting example of an arylamino group is -NHC6H5.
• ami do when used without the "substituted” modifier, refers to the group -NHR, in which R is acyl, as that term is defined above.
• a non-limiting example of an amido group is -NHC(0)CH3.
• alkylaminodiyl refers to the divalent group -NH-alkanediyl- -NH-alkanediyl-NH-, or -alkanediyl-NH-alkanediyl- When any of these terms is used with the "substituted" modifier one or more hydrogen atom attached to a carbon atom has been independently replaced by -OH, -F, -CI, -Br, -I, -NH2, -NO2, -CO2H, -CO2CH3, -CN, -SH, -OCH3, -OCH2CH3, -C(0)CH 3 , -NHCH3, -NHCH2CH3, -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , -C(0)N(CH 3 ) 2 , -OC(0)CH 3 , -NHC(0)CH 3 , -S(0) 2 OH, or -S(0)
• Excipient is a pharmaceutically acceptable substance formulated along with the active ingredient(s) of a medication, pharmaceutical composition, formulation, or drug delivery system. Excipients may be used, for example, to stabilize the composition, to bulk up the composition (thus often referred to as “bulking agents,” “fillers,” or “diluents” when used for this purpose), or to confer a therapeutic enhancement on the active ingredient in the final dosage form, such as facilitating drug absorption, reducing viscosity, or enhancing solubility. Excipients include pharmaceutically acceptable versions of antiadherents, binders, coatings, colors, disintegrants, flavors, glidants, lubricants, preservatives, sorbents, sweeteners, and vehicles.
• the main excipient that serves as a medium for conveying the active ingredient is usually called the vehicle. Excipients may also be used in the manufacturing process, for example, to aid in the handling of the active substance, such as by facilitating powder flowability or non-stick properties, in addition to aiding in vitro stability such as prevention of denaturation or aggregation over the expected shelf life. The suitability of an excipient will typically vary depending on the route of administration, the dosage form, the active ingredient, as well as other factors. [00131] As used herein, the term "IC50" refers to an inhibitory dose which is 50% of the maximum response obtained. This quantitative measure indicates how much of a particular drug or other substance (inhibitor) is needed to inhibit a given biological, biochemical or chemical process (or component of a process, i.e. an enzyme, cell, cell receptor or microorganism) by half.
• An "isomer" of a first compound is a separate compound in which each molecule contains the same constituent atoms as the first compound, but where the configuration of those atoms in three dimensions differs.
• the term "patient” or “subject” refers to a living mammalian organism, such as a human, monkey, cow, sheep, goat, dog, cat, mouse, rat, guinea pig, or transgenic species thereof.
• the patient or subject is a primate.
• Non-limiting examples of human patients are adults, juveniles, infants and fetuses.
• pharmaceutically acceptable refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues, organs, and/or bodily fluids of human beings and animals without excessive toxicity, irritation, allergic response, or other problems or complications commensurate with a reasonable benefit/risk ratio.
• “Pharmaceutically acceptable salts” means salts of compounds of the present invention which are pharmaceutically acceptable, as defined above, and which possess the desired pharmacological activity.
• Such salts include acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or with organic acids such as 1 ,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, 2-naphthalenesulfonic acid, 3-phenylpropionic acid, 4,4'-methylenebis(3-hydroxy-2-ene-l -carboxylic acid), 4-methylbicyclo[2.2.2]oct-2-ene- 1 -carboxylic acid, acetic acid, aliphatic mono- and dicarboxylic acids, aliphatic sulfuric acids, aromatic sulfuric acids, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, carbonic acid, cin
• Pharmaceutically acceptable salts also include base addition salts which may be formed when acidic protons present are capable of reacting with inorganic or organic bases.
• Acceptable inorganic bases include sodium hydroxide, sodium carbonate, potassium hydroxide, aluminum hydroxide and calcium hydroxide.
• Acceptable organic bases include ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine and the like. It should be recognized that the particular anion or cation forming a part of any salt of this invention is not critical, so long as the salt, as a whole, is pharmacologically acceptable. Additional examples of pharmaceutically acceptable salts and their methods of preparation and use are presented in Handbook of Pharmaceutical Salts: Properties, and Use (P. H. Stahl & C. G. Wermuth eds., Verlag Helvetica Chimica Acta, 2002).
• a "pharmaceutically acceptable carrier,” “drug carrier,” or simply “carrier” is a pharmaceutically acceptable substance formulated along with the active ingredient medication that is involved in carrying, delivering and/or transporting a chemical agent.
• Drug carriers may be used to improve the delivery and the effectiveness of drugs, including for example, controlled-release technology to modulate drug bioavailability, decrease drug metabolism, and/or reduce drug toxicity. Some drug carriers may increase the effectiveness of drug delivery to the specific target sites.
• Examples of carriers include: liposomes, microspheres (e.g. , made of poly (lactic-co-gly colic) acid), albumin microspheres, synthetic polymers, nanofibers, protein-DNA complexes, protein conjugates, erythrocytes, virosomes, and dendrimers.
• a "pharmaceutical drug” (also referred to as a pharmaceutical, pharmaceutical preparation, pharmaceutical composition, pharmaceutical formulation, pharmaceutical product, medicinal product, medicine, medication, medicament, or simply a drug) is a drug used to diagnose, cure, treat, or prevent disease.
• An active ingredient (AI) (defined above) is the ingredient in a pharmaceutical drug or a pesticide that is biologically active.
• active pharmaceutical ingredient (API) and bulk active are also used in medicine, and the term active substance may be used for pesticide formulations.
• Some medications and pesticide products may contain more than one active ingredient.
• the inactive ingredients are usually called excipients (defined above) in pharmaceutical contexts.
• Prevention includes: (1) inhibiting the onset of a disease in a subj ect or patient which may be at risk and/or predisposed to the disease but does not yet experience or display any or all of the pathology or symptomatology of the disease, and/or (2) slowing the onset of the pathology or symptomatology of a disease in a subject or patient which may be at risk and/or predisposed to the disease but does not yet experience or display any or all of the pathology or symptomatology of the disease.
• Treatment includes (1) inhibiting a disease in a subject or patient experiencing or displaying the pathology or symptomatology of the disease (e.g. , arresting further development of the pathology and/or symptomatology), (2) ameliorating a disease in a subject or patient that is experiencing or displaying the pathology or symptomatology of the disease (e.g. , reversing the pathology and/or symptomatology), and/or (3) effecting any measurable decrease in a disease in a subject or patient that is experiencing or displaying the pathology or symptomatology of the disease.
• inhibiting a disease in a subject or patient experiencing or displaying the pathology or symptomatology of the disease e.g. , arresting further development of the pathology and/or symptomatology
• ameliorating a disease in a subject or patient that is experiencing or displaying the pathology or symptomatology of the disease e.g. , reversing the pathology and/or symptomatology
• Monomers 2-(diethylamino)ethyl methacrylate (DEA-MA) and 2- aminoethyl methacrylate (AMA-MA) were purchased from Polyscience Company.
• Ovalbumin and OVA257-263, CpG ODN were purchased from Invivogen.
• Imject Alum was purchased from Thermo Scientific, LPS and Poly (I: C) were purchased from Sigma- Aldrich.
• OVA257-280 (SIINFEKLTEWTSSNVMEERKIKV (SEQ ID NO: 27)), E7 43 -62 (GQAEPDRAHYNIVTFCCKCD (SEQ ID NO: 26)), E7 4 9-57 (RAHYNIVTF (SEQ ID NO: 28)), Gpl 00 2 i-4i(VGALEGSRNQDWLGVPRQLVT (SEQ ID NO: 29)), Trphi4- 237(SHEGPAFLTWHRYHLLQLERDMQE (SEQ ID NO: 5)), Trp2i73- i96(QPQIANCSVYDFFVWLHYYSVRDT (SEQ ID NO: 6)), Obsll T i764M (EGVELCPGNKYEMRRHGTTHSLVIHD (SEQ ID NO:
• Dpagtlv2i3 L (EAGQSLVISASIIVFNLLELEGDYR (SEQ ID NO: 33)) were synthesized by Biomatik.
• PEG-PLA was purchased from Advanced Polymer Materials Inc. (Montreal, QC, Canada).
• Other solvents and reagents were purchased from Sigma-Aldrich or Fisher Scientific Inc.
• Monomer AMA-MA was recrystallized twice in isopropanol and ethyl acetate (3:7) before use.
• New monomers including 2-(heptamethyleneimino)ethyl methacrylate (C8A- MA), 2-(4-methylpiperidineleneimino)ethyl methacrylate (C6S1A-MA), 2-(3,5- dimethylpiperidineleneimino)ethyl methacrylate (C6S2A-MA) were synthesized following a previously published procedure (Zhou et al , 2012).
• PEG-&-PR copolymers were synthesized by atom transfer radical polymerization (ATRP) following similar procedures previously reported (Tsavrevsky et al. , 2007). The dye free copolymers were used in polymer characterizations.
• PEG-&-PDPA is used as an example to illustrate the procedure. First, DPA-MA (1.48 g, 7 mmol), PMDETA (21 ⁇ , 0.1 mmol), and MeO-PEGii4-Br (0.5 g, 0.1 mmol) were charged into a polymerization tube. Then a mixture of 2-propanol (2 mL) and DMF (2 mL) was added to dissolve the monomer and initiator.
• AMA-MA was introduced in the PEG-6-PR copolymers for the conjugation of dyes.
• Synthesis of PEG-i-(PR-r-AMA) copolymers followed the procedure described above (Zhou et al , 201 1 ; 2012).
• PEG-i-(PR-r-AMA) (10 mg) was dissolved in 2 mL DMF. Then the NHS-ester (1.5 equivalences for Dye-NHS) was added.
• the copolymers were purified by preparative gel permeation chromatography (PLgel Prep 10 m 10E3 A 300x250 columns by Varian, THF as eluent at 5 mL/min) to remove the free dye molecules.
• the produced PEG-i-(PR-r-Dye) copolymers were lyophilized and kept at -20 °C for storage.
• mice were prepared following a solvent evaporation method as previously published (Zhou et al. 2012).
• the FRET experiment was designed to investigate the polymer and protein interaction at different ratio.
• the Cy3.5 conjugated PC7A 100 ⁇ g/mL was incubated with Alexa Fluor 647-labelled OVA (20 ⁇ g/mL) in PBS buffer, pH 7.4. After 0.5 hours incubation, the fluorescence emission spectra were obtained on a Hitachi fluorometer (F-7500 model). The samples were excited at 590 nm, and the emission spectra were collected from 600 to 750 nm.
• ICG-encoded PC7A NP (30 ⁇ g per mice) was injected subcutaneously at the tail base of C57BL/6 mice. NP distribution was imaged using a clinical camera (SPY Elite®). Animals were sacrificed at 24h after injection of NP, major organs and inguinal and axillary LNs were excised and imaged.
• mice Female C57BL/6 mice (6-8 weeks) were obtained from the UT southwestern breeding core. INF- ⁇ R mice were kindly provided by Dr. David Farrar (UT Southwestern). STING ⁇ mice,AfyD «*1 ⁇ 2iice, TRI ⁇ mice C57BL/6- Tg (TcraTcrb)1100Mjb/J (CD45.2, H-2 b ) (OT-I) mice, C57BL/6- CD45.1 mice were purchased from the Jackson laboratory. were crossed in our lab. cGas ⁇ mice were generated as previously described 4 . All these strains were maintained on C57BL/6J background.
• mice were randomly allocated by blinded investigators to each group.
• STING gt/gt and cGAS ⁇ ' ⁇ BMDMs were derived from corresponding knockout mice, and then cultured in M-CSF containing medium for 6-7days.
• THP-1 cells were purchased from ATCC and the inventors established THP-1 cell lines stably expressing shRNA targeting hSTING and hcGAS as described before (Collins et al , 2015), these THP-1 cell lines were grown in suspension RPMI media (Gibco) supplemented with 10% FBS, 0.05% ⁇ - mercaptoethanol (Sigma), and Pen/strep.
• B16-OVA cells were kindly provided by Dr.
• TC-1 cells were kindly provided by Dr. T. C. Wu at John Hopkins University, MC38 cells were kindly provide by Dr. Yangxin Fu(UT Southwestern). All cell lines were routinely tested using mycoplasma contamination kit (R&D). Cells were cultured in complete medium (DMEM, 10% fetal bovine serum, 100 U/mL penicillin G sodium and 100 ⁇ g/mL streptomycin (Pen/Strep), MEM non-essential amino acids (all from Invitrogen), and 20 ⁇ -mercaptoethanol( -ME)) at 37°C in 5% CO2 and the normal level of O2.
• DMEM fetal bovine serum
• Pen/Strep penicillin G sodium
• streptomycin Pen/Strep
• MEM non-essential amino acids all from Invitrogen
• 20 ⁇ -mercaptoethanol( -ME) 20 ⁇ -mercaptoethanol( -ME)
• mice Groups of C57BL/6 mice were injected (OVA 10 ⁇ g plus nanoparticles 30 ⁇ g or other adjuvants with the same dose) subcutaneously at the tail base of C57BL/6 mice.
• Imject Alum (4 mg per mouse, 50 ⁇ 1:50 ⁇ mixture with the antigen solution) was used by volume ratio as recommended by manufacture.
• naive C57BL/6 mice were sacrificed and spleenocytes were collected.
• Half of the spleenocytes were pulsed with OVA257-263 or E749-57 peptides for 2 h in complete media at 37 °C.
• the impulsed and peptide-pulsed cells were labeled with 0.5 or 0.05 ⁇ Carboxyfluorescein succinimidyl ester (CFSE), respectively, in serum free media for 15 mins.
• mice were immunized with different vaccines on day 0 and 14. On day 21, 50 ⁇ . of blood was drawn from tail vein and the antigen-specific IgGl and IgG2c in serum were measured by ELISA.
• ELISA assay flat-bottomed 96-well plates (Nunc, Rochester, NY) were precoated with OVA protein at a concentration of 0.5 ⁇ g protein/well in 50 mM carbonate buffer (pH 9.6) at 4 °C overnight, which were then blocked with 5% Glycine.
• Antisera obtained from immunized animals were serially diluted from 10 2 to 10 6 in PBS-0.05% Tween (PBS-T), pH 7.4, and were added to the wells and incubated at 37 °C for 1 h.
• Goat anti-mouse IgGl and IgG2c (HRP) (Abeam, Cambridge, MA) were used at a dilution of 1 : 10,000 in PBS-T-1% BSA for labeling.
• HRP substrates After adding the HRP substrates, optical densities were determined at a wavelength of 450 nm in an ELISA plate reader (Bio-Rad, Hercules, CA).
• mice were performed with PBS alone, OVA-AF647, or nanoparticle plus OVA- AF647 treatments.
• mice were sacrificed and inguinal lymph nodes were removed, teased with 26 gauge needles and then passed through a 70- ⁇ cell strainer (BD) to recover a cell suspension.
• the lymph node cell suspension was stained with PI and anti-CDl lc-FITC, anti-CD l ib-pacific blue, anti-B220-APC-Cy7, anti-CD8a-PE-Cy7.
• CD8a + DC cells CDl lc + CDl lb-B220-CD8a +
• CD8a DC cells CDl lc + CD8a "
• macrophage cells CDl lb + CDl lc " B220 "
• B cells B220 + CDl lc "
• mice were carried out with PBS alone, or PC7A-Cy5 (30 ⁇ g) treatments.
• PC7A-Cy5 (30 ⁇ g) treatments.
• mice were sacrificed, inguinal lymph nodes and subcutaneous tissue were removed, and digested in collagenase IV (Sigma- Aldrich) solution for 25 mins at 37°C. Tissue was then passed through a 70- ⁇ cell strainer (BD) to recover a cell suspension. All the cell suspension were stained with PI and anti-CDl lc-FITC, anti- MHCII-BV605, anti-CD45.2-Apc-Cy7.
• BD 70- ⁇ cell strainer
• pIRF3 staining For intracellular pIRF3 staining, cells were permeabilized by the Fixation/Permeabilization kit (BD Cat#554714). After blocking with mouse serum, cells were stained with pIRF3 antibody (Cell Signaling, Cat # 4947) and subsequently were stained with anti-rabbit IgG-PE secondary antibody (Biolegend). Flow cytometry (LSRII, BD) was performed on stained cell suspensions and analyzed with FlowJo® software (Tree Star Inc. Ashland, OR).
• Bone marrow-derived dendritic cells were generated by culturing bone marrow cells flushed from femurs of C57BL/6J mice in DC media: DMEM supplemented with 10% FBS, pen/strep, sodium pyruvate and 20 ng/mL GM-CSF. Media was half replaced every 2 days; non-adherent and loosely adherent immature dendritic cells (DCs) were collected on day 6 and phenotyped by determining expression of CDl lc (routinely 60-80% CD1 lc + ).
• OVA-AF647 (2ug/mL) or mixture of OVA-AF647 with different nanoparticles (50 ⁇ g/mL) was incubated with murine bone marrow-derived dendritic cells (BMDCs) at 37°C for 4 hours and quantified using the mean fluorescence intensity (MFI) of cells by FACS.
• MFI mean fluorescence intensity
• BMDCs were incubated with OVA alone or mixture of OVA with different nanoparticles at 37°C for 18-20 hours, then the OVA257-267 presented on the MHC-I on cell surface were detected by monoclonal antibody 25mAb-D1.16, an antibody specifically recognize OVA peptide SIINFEKL bound to H-2K b .
• BMDCs were incubated with 3 ⁇ g/mL OVA alone or mixture of OVA with different nanoparticles (50 ⁇ g/mL) at 37°C for 18 h.
• CD8 + T lymphocytes from OT-I mice were selected by magnetic separation (MACS system; Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's indications. The purity of CD8 + T lymphocytes was >95%.
• CD8 + T cells were plated at 2 ⁇ 10 5 cells/well in 96-well plates (Costar; Corning, Inc., Coming, NY) in RPMI media containing 10% FCS and 2 ⁇ 10 5 impulsed, or antigen- pulsed BMDCs that were added for 24 h.
• Cell culture supernatants were collected and analyzed for cytokine content using mouse TH1/TH2 9-Plex Ultra-sensitive Kit (Meso Scale Discovery). Samples were run in triplicate.
• Spleens were harvested from B6 CD45.2 + OT-I mice, CD8 + T cells from cell suspensions were isolated by magnetic bead separation on a MACS column. 5 ⁇ 10 4 OT-1 CD8 + T cells were transferred into B6 CD45.1 + mice via intravenous (i.v.) injection and allowed to acclimate for 1 day prior to immunization. 1 day later, groups of CD45.1 + mice were immunized with PBS alone, OVA(10 ⁇ g), or nanoparticle (30 ⁇ g) plus OVA subcutaneously at the tail base.
• spleens were harvested and dispersed into single-cell suspensions, stained with anti-CD8-PE-cy7, APC-conjugated H-2Kb/OVA (SIINFEKL) tetramer (NIH) for flow cytometry analysis.
• SIINFEKL APC-conjugated H-2Kb/OVA
• Antibodies were purchased from Biolegend. The following primary antibodies were used: anti-CD 16/CD32 (Biolegend, Cat#: 101301, clone: 93), anti-CD8-PE- cy7 (Biolegend, Cat#: 100721, clone: 53-6.7), anti-CD l lc-FITC (Biolegend, Cat#: 117305, clone: N418) and anti-CD l lb-Pacif blue (Biolegend, Cat#: 101223, clone: Ml/70), anti- B220-APC-cy7 (Biolegend, Cat#: 103223, clone: RA3-6B2), anti-CD86-PE (Biolegend, Cat#: 105007, clone: GL-1), anti- H-2K b bound to SIINFEKL-APC (Biolegend, Cat#: 141605, clone:25-D1.16), anti-CD45.2-APC (Biolegend, Cat
• Subcutaneous tissues were taken at indicated time points after injection with OVA-PC7A NP (OVA 10 ⁇ g, PC7A 150 ⁇ g) or the same dose of different adjuvants.
• OVA-PC7A NP OVA 10 ⁇ g, PC7A 150 ⁇ g
• BMDM bone marrow cells
• FBS fetal bovine serum
• conditioned media from L929 cell culture.
• mature macrophages were harvested and cultured on 12-well plates for experiments (Collins et al. , 2015).
• Total RNAs were extracted by TRIzol (Invitrogen) from cells or tissues according to the manufacturer's instructions.
• q-RT-PCR were performed as previously described (Li et al. , 2013; Collins et al. , 2015). Samples were run in triplicate. The following primers were used for q-RT-PCR.
• mIRF7 ATGCACAGATCTTCAAGGCCTGGGC (SEQ ID NO: 16);
• mRPL19 AAATCGCCAATGCCAACTC (SEQ ID NO: 20);
• hCXCLlO TGGCATTCAAGGAGTACCTC (SEQ ID NO: 22);
• hGAPDH ATGACATCAAGAAGGTGGTG (SEQ ID NO: 24);
• tumor tissues were digested by 1 mg/mL collagenase IV (Sigma-Aldrich) and 0.2 mg/mL DNase I (Sigma-Aldrich) for 45 minutes at 37°C. Cells were then stained with antibodies against PD-L1, CDl lb, Gr-1, F4/80, CD1 lc, and CD45 (Biolegend).
• the pH-sensitive polymer library of PEG-&-PR with 70 repeating unit of PR segment was synthesized using an atom transfer radical polymerization method.
• Dye conjugated polymers were synthesized by reacting PEG-Z>-PR(NH2) with NHS-Dye in N,N- dimethylformamide.
• the PC7A nanovaccine was freshly prepared by physical mixing of the PC7A nanoparticle with protein or peptide antigens in water.
• C57BL/6 mice female, 6-8 weeks old, Breeding Core on campus
• All animal procedures were approved by the Institutional Animal Care and Use Committee at the University of Texas Southwestern Medical Center.
• BMDMs were transfected with 5 ⁇ g of DNase I (Roche) by transfection reagent DOTAP (Roche) according to manufacturer's instructions. After incubating the cells with DOTAP-DNase I or DOTAP alone for lhr, cells were washed to remove excess of transfection reagent and enzyme and were then incubated with PC7A at 400 Hg/ml for 9 hr. CXCL10 were measured by RT-PCR.
• PC7A-biotin 200 ⁇ g/ml was incubated with THP-1 cells for 8 hrs, and then cells were collected and lysed in RIPA buffer (Sigma R0278). Lysates were precipitated with streptavidin-modified dynabeads (BD 557812). Samples were analyzed using SDS-PAGE and Western blots by rabbit anti-STING antibody (Cell Signaling, Cat # 13647).
• the homogenate samples were centrifuged at 7000*g and 4°C for 10 min. Then 50 ⁇ of supernatant was mixed with 50 ⁇ substrate solution.
• the composition of the substrate solution was 100 mM potassium phosphate buffer (pH 6.5), 50 ⁇ methylene blue, 20 ⁇ g catalase, 50 mM ascorbate, and 0.4 mM L-TRP. After incubation of the reaction mixture at 37°C, samples were acidified with 3% perchloric acid and centrifuged at 7000* g and 4°C for 10 min. The concentrations of the products were measured by HPLC. Enzyme activity was expressed as the product content per hour per gram of tissue protein.
• OVA loading efficiency inside micelle nanoparticles was measured by an ultrafiltration method. Briefly, micelle nanoparticles (300 ⁇ g/mL) from different polymers were mixed with AF647-labelled OVA (100 ⁇ g/mL) for 30 min. After OVA loading, free OVA was removed from OVA-loaded nanoparticles by ultrafiltration tube with a molecular weight cutoff of 100 kD. The concentration of free OVA was measured on a Hitachi fiuorometer (F-7500 model) with excitation wavelength at 640 nm. The loading efficiency was calculated using the equation below: Total OVA-Free OVAget _ _ N /
• HlNl HA PR8 antigen 5 ⁇ g/mL in PBS
• Plates were blocked with TBS-3% (wt/vol) bovine serum albumin (BSA).
• BSA bovine serum albumin
• Samples were added to plate at a 1 : 10000 dilution.
• HRP- conjugated goat anti-mouse IgG H+L
• HRP-conjugated goat anti-mouse IgGl or IgG2b antibodies were added at a dilution of 1 :5000.
• the plate was developed with 3,3',5,5'-tetramethylbenzidine substrate and the OD at 450 nm was measured.
• influenza A/PR/8/34 (HlNl) virus was diluted in sterile PBS to lOx (700 pfu/mouse) MLD50. Mice were sedated using ketamine (30 mg/ml)/xylazine (4 mg/ml) intraperitoneally (i.p.) and virus was administered intranasally in a total volume of 40 ⁇ , split evenly between nares. After virus challenge, mice received atipamezole (0.63 mg/ml) i.p. and were subsequently monitored for weight loss and mortality for 14 days. Mice were humanely sacrificed when weight loss exceeded 30%.
• UPS ultra-pH sensitive
• the UPS library consists of copolymers containing tertiary amines with linear or cyclic side chains (FIG. 1A and FIG. 5A) with each component rendering sharp pH buffering at corresponding pKa (FIGS. 5B-C).
• Ovalbumin (OVA) was used as a model antigen. OVA loading efficiency was measured to be >75% across different polymer nanoparticles (FIG. 6A).
• OVA-specific CTL response was quantified by an established in vivo cytotoxicity assay (FIG. 1A) (Barber et al , 2015). Briefly, OVA-polymer NP was first injected subcutaneously at the tail base of C57BL/6 mice. After 7 days, OVA epitope (SIINFEKL) specific CTL effect was determined by measuring the killing rate of CFSE- labeled target cells. Flow cytometry data showed that PC7A NP allowed the highest OVA- specific splenocyte killings (82%) compared to other cyclic amines (e.g. , PC6A, substituted PC6As and PC8A) as well as linear tertiary amines (FIG.
• cyclic amines e.g. , PC6A, substituted PC6As and PC8A
• PC7A NP yielded approximately two-fold stronger CTL response compared to PC6S1A and PEPA NPs with comparable pKa's (6.9-7.0). In the linear series, PEPA had the highest CTL response compared to other copolymers.
• pH transition i.e. , 6.9 that targets early endosomal pH
• polymer architecture i.e. , cyclic seven-membered ring
• OVA-PC7A NP induced approximately 20-fold higher CTL response over OVA- Alum (4.3%) or OVA-LPS that stimulates the TLR4 pathway (3.7%) (Poltorak et al, 1998), and 3.6-fold higher than OVA-CpG that stimulates the TLR9 pathway (23%) (Hemmi et al , 2000).
• OVA-specific antibody responses from the sera of immunized mice collected 7 days after boosting showed that mice vaccinated with PC7A NP generated similar titers of OVA-specific IgGl response comparable to those by Alum or LPS (FIG. 1C).
• PC7A NP also generated similar titers of OVA-specific IgG2c antibody compared to those immunized with OVA plus CpG or LPS (FIG. ID). Altogether, the inventors conclude that PC7A NP was able to induce a robust antigen-specific CTL, Thl and Th2 responses with comparable or better efficacy than several established adjuvants.
• the inventors examined the expressions of IFN-stimulated genes (ISGs) in the local tissues (Trinchieri et al , 2010) over time after subcutaneous injection of PC7A NP.
• Poly(LC) was used as a positive control (Alexopoulou et al , 2001). Results show that Poly(LC) was able to elicit higher response in IRF7 and CXCL10 expressions in the early time points from 2 to 8 h than PC7A NP.
• PC7A NP produced stronger responses than both Poly(LC) and PD5ANP groups (FIGS. 3B-C).
• IFN- ⁇ R ⁇ IFN receptor
• TLR Toll-like receptors
• MAVS MAVS and STING are known to activate the type I interferon pathways (Zitvogel et al , 2015; Baccala et al , 2007).
• Cy5-labeled PC7A polymer was employed to quantify NP uptake in cells and phosphorylated IRF3 (pIRF3) was used to detect the activation of STING-type I IFN pathway (Woo et al, 2014).
• pIRF3 phosphorylated IRF3
• NP+ cells expressed a DC cell marker (CDl lc+) which was further corroborated by MHC-II+ expression (FIG. 10B).
• CD45+ leukocytes internalized significantly higher amount of PC7A NPs than CD45- cells.
• the inventors did not observe any significant increase in the pIRF3 levels.
• significantly elevated pIRF3 levels were found in the NP+ cells over NP- cells.
• Further analysis of CD45+NP+ cells showed 95% of cell population have CDl lc+ marker (lower panel in FIG. 10D). Based on these data, the inventors conclude that at both the injection site and draining LNs, APCs (especially DCs) were the major cell population that took up PC7A NPs and subsequently activated STING- type I IFN pathway.
• a physical mixture of antigenic peptides OVA257-280, 0.5 ⁇ g
• PC7A NP 30 ⁇ g
• Different nanovaccine groups were subcutaneously injected 5 days after tumor inoculation, followed by a booster shot 5 days later (FIG. 4B).
• PBS control group all the animals died in 20 days.
• OVA257-280 alone, PC7A NP alone or OVA257- 280-PD5A NP groups did not offer any significant tumor growth inhibition or survival benefit over the PBS control (FIGS. 11A-B).
• OVA 2 57-28o-CpG and OVA 2 57-28o-Poly(I:C) groups offered a minor degree of immune protection (FIGS. 4B-C). Still, all the animals died before day 40. In contrast, OVA257-280-PC7A NP achieved the maximum therapeutic efficacy, where 50% of animals survived over 40 days.
• B16-F10 melanoma the inventors used a cocktail of either tumor associated antigens (Gpl002i-4i, Trphi4-237, Trp2i73-i96) or neoantigens (ObsllTi764M, Kifl 8b K 739N, Def8 R 255G) (Kreiter et al , 2015) in PC7A NP (0.5 ⁇ g for each peptide, 30 ⁇ g polymer).
• the 7-membered cyclic amine side chain structure in PC7A NP rendered a relatively high transition pH (i.e. , 6.9) providing pH-specific proton sponge effect at early endosomal pH (6.5-7.0) and rigid configuration of protonated unimers for membrane disruption (FIGS. 8A-B).
• Early endosomal release of tumor antigens into the cytosol avoids lysosomal degradation leading to increased antigen cross-presentation on the cell surface.
• This unique membrane disruption capability may also be responsible for introducing trace amount of DNA into cytosol, which subsequently activates cytosolic cGAS-STING pathway for innate stimulation 21 .
• STING pulldown assay and ITC experiment uncovered direct binding of PC7A to STING.
• the PC7A-STING interaction appeared to be specific, as supported by the lack of STING CTD pulldown by PEPA and PD5A copolymers (particularly, PEPA has the same transition pH as PC7A but lacks the ring structure), as well as negligible binding between PC7A and BS A by the ITC experiment.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Mycology (AREA)
• Microbiology (AREA)
• Immunology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Oncology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nanotechnology (AREA)
• Virology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Biomedical Technology (AREA)
• Optics & Photonics (AREA)
• Physics & Mathematics (AREA)
• Communicable Diseases (AREA)
• Pulmonology (AREA)
• Dermatology (AREA)
• Inorganic Chemistry (AREA)
• Tropical Medicine & Parasitology (AREA)
• Biophysics (AREA)
• General Engineering & Computer Science (AREA)
• Medical Informatics (AREA)
• Molecular Biology (AREA)
• Crystallography & Structural Chemistry (AREA)
• Biotechnology (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Medicinal Preparation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (8)

Applications Claiming Priority (2)

Publications (1)

Family

ID=59743242

Family Applications (1)

Country Status (9)

Cited By (21)

Families Citing this family (8)

Citations (27)

Family Cites Families (15)

• 2017
  • 2017-03-02 KR KR1020187027939A patent/KR20180114946A/ko not_active Ceased
  • 2017-03-02 AU AU2017225769A patent/AU2017225769B2/en active Active
  • 2017-03-02 CA CA3016457A patent/CA3016457A1/en active Pending
  • 2017-03-02 EP EP17760821.3A patent/EP3423044A4/en active Pending
  • 2017-03-02 US US16/081,911 patent/US11376324B2/en active Active
  • 2017-03-02 CN CN201780027045.XA patent/CN109069440A/zh active Pending
  • 2017-03-02 WO PCT/US2017/020451 patent/WO2017151922A1/en not_active Ceased
  • 2017-03-02 JP JP2018545910A patent/JP2019511483A/ja active Pending
  • 2017-03-02 MX MX2018010586A patent/MX2018010586A/es unknown

Patent Citations (27)

Non-Patent Citations (73)

Also Published As

Similar Documents

Legal Events